CN1187081C - 一种治疗淋巴结关系型癌症的中药 - Google Patents
一种治疗淋巴结关系型癌症的中药 Download PDFInfo
- Publication number
- CN1187081C CN1187081C CNB031229891A CN03122989A CN1187081C CN 1187081 C CN1187081 C CN 1187081C CN B031229891 A CNB031229891 A CN B031229891A CN 03122989 A CN03122989 A CN 03122989A CN 1187081 C CN1187081 C CN 1187081C
- Authority
- CN
- China
- Prior art keywords
- cancer
- herba
- radix
- chinese medicine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 204
- 239000003814 drug Substances 0.000 title claims abstract description 191
- 201000011510 cancer Diseases 0.000 title claims abstract description 189
- 150000001875 compounds Chemical class 0.000 title abstract description 18
- 210000001165 lymph node Anatomy 0.000 claims abstract description 51
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 29
- 239000004863 Frankincense Substances 0.000 claims abstract description 10
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 10
- 241001116779 Lemmaphyllum Species 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 60
- 210000000582 semen Anatomy 0.000 claims description 12
- 241000717739 Boswellia sacra Species 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 241001057584 Myrrha Species 0.000 claims description 8
- 241000756943 Codonopsis Species 0.000 claims description 7
- 241000533849 Gleditsia Species 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 4
- 241000563984 Ampelopsis Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 82
- 210000004185 liver Anatomy 0.000 abstract description 47
- 239000000843 powder Substances 0.000 abstract description 38
- 210000000496 pancreas Anatomy 0.000 abstract description 22
- 241000219099 Parthenocissus quinquefolia Species 0.000 abstract description 9
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 240000007311 Commiphora myrrha Species 0.000 abstract description 3
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract description 3
- 230000002052 anaphylactic effect Effects 0.000 abstract description 3
- 241000218671 Ephedra Species 0.000 abstract description 2
- 235000018958 Gardenia augusta Nutrition 0.000 abstract description 2
- 235000018081 Hibiscus syriacus Nutrition 0.000 abstract description 2
- 244000130592 Hibiscus syriacus Species 0.000 abstract description 2
- 240000003146 Lobelia chinensis Species 0.000 abstract description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract description 2
- 241000157511 Oldenlandia Species 0.000 abstract description 2
- 241000123725 Sophora tonkinensis Species 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241001254604 Angelica pubescens Species 0.000 abstract 1
- 241001674044 Blattodea Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000735527 Eupatorium Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 244000230012 Gleditsia triacanthos Species 0.000 abstract 1
- 235000013813 Gleditsia triacanthos Nutrition 0.000 abstract 1
- 241001646834 Mesona Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 description 72
- 230000000694 effects Effects 0.000 description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- 210000004072 lung Anatomy 0.000 description 52
- 230000000144 pharmacologic effect Effects 0.000 description 48
- 230000008859 change Effects 0.000 description 47
- 238000001035 drying Methods 0.000 description 45
- 230000006870 function Effects 0.000 description 45
- 230000009471 action Effects 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 40
- 238000000605 extraction Methods 0.000 description 39
- 208000024891 symptom Diseases 0.000 description 39
- 230000004060 metabolic process Effects 0.000 description 38
- 230000008569 process Effects 0.000 description 38
- 239000004615 ingredient Substances 0.000 description 37
- 239000007788 liquid Substances 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 36
- 210000000056 organ Anatomy 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 36
- 206010013786 Dry skin Diseases 0.000 description 35
- 210000003734 kidney Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 34
- 210000003932 urinary bladder Anatomy 0.000 description 34
- 210000002751 lymph Anatomy 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 32
- 238000012360 testing method Methods 0.000 description 30
- 238000010438 heat treatment Methods 0.000 description 29
- 230000000149 penetrating effect Effects 0.000 description 29
- 238000001959 radiotherapy Methods 0.000 description 29
- 230000003110 anti-inflammatory effect Effects 0.000 description 28
- 210000001113 umbilicus Anatomy 0.000 description 28
- 238000010298 pulverizing process Methods 0.000 description 24
- -1 saccharides chemical compounds Chemical class 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 229940079593 drug Drugs 0.000 description 22
- 230000001926 lymphatic effect Effects 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 21
- 230000036407 pain Effects 0.000 description 21
- 230000001737 promoting effect Effects 0.000 description 21
- 230000000202 analgesic effect Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 238000011160 research Methods 0.000 description 20
- 238000003306 harvesting Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 17
- 238000012546 transfer Methods 0.000 description 17
- 208000004880 Polyuria Diseases 0.000 description 16
- 230000004087 circulation Effects 0.000 description 16
- 230000007123 defense Effects 0.000 description 16
- 230000035619 diuresis Effects 0.000 description 16
- 210000003240 portal vein Anatomy 0.000 description 16
- 208000007536 Thrombosis Diseases 0.000 description 15
- 229930182470 glycoside Natural products 0.000 description 15
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 150000002338 glycosides Chemical class 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 12
- 210000000232 gallbladder Anatomy 0.000 description 12
- 230000002147 killing effect Effects 0.000 description 12
- 230000004203 pancreatic function Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229950005143 sitosterol Drugs 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 230000036592 analgesia Effects 0.000 description 11
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 210000004907 gland Anatomy 0.000 description 11
- 230000032630 lymph circulation Effects 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- 235000012771 pancakes Nutrition 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 230000009931 harmful effect Effects 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 9
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 8
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000000476 body water Anatomy 0.000 description 8
- 229940074360 caffeic acid Drugs 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- 244000045947 parasite Species 0.000 description 8
- 239000003507 refrigerant Substances 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 229940096998 ursolic acid Drugs 0.000 description 8
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 7
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 7
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 7
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 7
- 201000008275 breast carcinoma Diseases 0.000 description 7
- 235000004883 caffeic acid Nutrition 0.000 description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 229960001231 choline Drugs 0.000 description 7
- 239000000812 cholinergic antagonist Substances 0.000 description 7
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 7
- 238000001784 detoxification Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000003128 head Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Natural products CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 7
- 210000003563 lymphoid tissue Anatomy 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 229940100243 oleanolic acid Drugs 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 7
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 7
- 230000000630 rising effect Effects 0.000 description 7
- 230000002048 spasmolytic effect Effects 0.000 description 7
- 201000008827 tuberculosis Diseases 0.000 description 7
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 229920001202 Inulin Polymers 0.000 description 6
- 208000033809 Suppuration Diseases 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- 229940076810 beta sitosterol Drugs 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 6
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 6
- 229940029339 inulin Drugs 0.000 description 6
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 6
- 229960004555 rutoside Drugs 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 5
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 5
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 5
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 5
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 5
- 235000001785 ferulic acid Nutrition 0.000 description 5
- 229940114124 ferulic acid Drugs 0.000 description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000004880 lymph fluid Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 229940098695 palmitic acid Drugs 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 230000007096 poisonous effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 235000015500 sitosterol Nutrition 0.000 description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 5
- CVRQUKAFPCFUQW-UHFFFAOYSA-N 2-[2,2-dimethyl-8-(3-methylbut-2-enyl)chromen-6-yl]-7-hydroxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C2=CC=C(O)C(CC=C(C)C)=C2OC1C(C=C1CC=C(C)C)=CC2=C1OC(C)(C)C=C2 CVRQUKAFPCFUQW-UHFFFAOYSA-N 0.000 description 4
- OQIOHYHRGZNZCW-UHFFFAOYSA-N 2-methyl-5-propan-2-ylbenzene-1,4-diol Chemical compound CC(C)C1=CC(O)=C(C)C=C1O OQIOHYHRGZNZCW-UHFFFAOYSA-N 0.000 description 4
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 4
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 4
- JEDBBFHVVHKMKS-UHFFFAOYSA-N 5,7-dimethoxy-8-(3-methylbut-2-enoyl)chromen-2-one Chemical compound C1=CC(=O)OC2=C(C(=O)C=C(C)C)C(OC)=CC(OC)=C21 JEDBBFHVVHKMKS-UHFFFAOYSA-N 0.000 description 4
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- PKRPFNXROFUNDE-LLVKDONJSA-N Byakangelicin Chemical compound O1C(=O)C=CC2=C1C(OC[C@@H](O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-LLVKDONJSA-N 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 4
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 4
- 150000004056 anthraquinones Chemical class 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 description 4
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 4
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 4
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 4
- 239000011449 brick Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 208000019065 cervical carcinoma Diseases 0.000 description 4
- 229940074393 chlorogenic acid Drugs 0.000 description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000001827 electrotherapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- BJQWYEJQWHSSCJ-UHFFFAOYSA-N heptacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC BJQWYEJQWHSSCJ-UHFFFAOYSA-N 0.000 description 4
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 4
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 4
- 210000003692 ilium Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 235000001510 limonene Nutrition 0.000 description 4
- 229940087305 limonene Drugs 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000003739 neck Anatomy 0.000 description 4
- IGGUPRCHHJZPBS-UHFFFAOYSA-N nonacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC IGGUPRCHHJZPBS-UHFFFAOYSA-N 0.000 description 4
- 230000001473 noxious effect Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 description 4
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 4
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 4
- STFNGWNFASVBRR-CQSZACIVSA-N villosol Chemical compound O([C@H](CC1=C2O3)C(C)=C)C1=CC(O)=C2C(=O)C1=C3COC2=C1C=C(OC)C(OC)=C2 STFNGWNFASVBRR-CQSZACIVSA-N 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- CXENHBSYCFFKJS-UHFFFAOYSA-N α-farnesene Chemical compound CC(C)=CCCC(C)=CCC=C(C)C=C CXENHBSYCFFKJS-UHFFFAOYSA-N 0.000 description 4
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- VSMWRDYVLPCABE-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-6h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound C1=C2OCOC2=CC(C2=C3C=C4OCOC4=CC3=CC3=C2COC3=O)=C1 VSMWRDYVLPCABE-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- 208000018501 Lymphatic disease Diseases 0.000 description 3
- 241001093152 Mangifera Species 0.000 description 3
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- ANFSXHKDCKWWDB-UHFFFAOYSA-N O-methyldiphyllin Natural products C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C(OC)=C3C=C(C(=CC3=2)OC)OC)=C1 ANFSXHKDCKWWDB-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 239000003560 cancer drug Substances 0.000 description 3
- ZERVJPYNQLONEK-UHFFFAOYSA-N canthin-6-one Chemical compound C12=CC=CC=C2N2C(=O)C=CC3=NC=CC1=C32 ZERVJPYNQLONEK-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 210000003109 clavicle Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 208000013219 diaphoresis Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000003760 hair shine Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229930190997 justicidin Natural products 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 229940043357 mangiferin Drugs 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 3
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- LHXDLQBQYFFVNW-XCBNKYQSSA-N (+)-fenchone Chemical compound C1C[C@]2(C)C(=O)C(C)(C)[C@H]1C2 LHXDLQBQYFFVNW-XCBNKYQSSA-N 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 2
- QTAGQHZOLRFCBU-CYBMUJFWSA-N (+)-oxypeucedanin Chemical compound CC1(C)O[C@@H]1COC1=C(C=CO2)C2=CC2=C1C=CC(=O)O2 QTAGQHZOLRFCBU-CYBMUJFWSA-N 0.000 description 2
- FQEQMASDZFXSJI-RWMBFGLXSA-N (-)-Anagyrine Natural products C([C@@H]12)CCCN1C[C@H]1C3=CC=CC(=O)N3C[C@@H]2C1 FQEQMASDZFXSJI-RWMBFGLXSA-N 0.000 description 2
- 229930006731 (1S,4R)-fenchone Natural products 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- AIFRLZKCLIPEMC-UKTHLTGXSA-N (e)-1-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-3-[2,2-dimethyl-8-(3-methylbut-2-enyl)chromen-6-yl]prop-2-en-1-one Chemical compound C=1C=2C=CC(C)(C)OC=2C(CC=C(C)C)=CC=1\C=C\C(=O)C1=CC=C(O)C(CC=C(C)C)=C1O AIFRLZKCLIPEMC-UKTHLTGXSA-N 0.000 description 2
- JXBSHSBNOVLGHF-UHFFFAOYSA-N 10-cis-Dihydrofarnesen Natural products CC=C(C)CCC=C(C)CCC=C(C)C JXBSHSBNOVLGHF-UHFFFAOYSA-N 0.000 description 2
- MBDOYVRWFFCFHM-UHFFFAOYSA-N 2-hexenal Chemical compound CCCC=CC=O MBDOYVRWFFCFHM-UHFFFAOYSA-N 0.000 description 2
- HHXYJYBYNZMZKX-PYQRSULMSA-N 22(29)-Hopene Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(=C)C HHXYJYBYNZMZKX-PYQRSULMSA-N 0.000 description 2
- HHXYJYBYNZMZKX-UHFFFAOYSA-N 3,4:15,16-diepoxy-7-oxo-13(16),14-clerodadien-20,12-olide-(3alpha,4alpha)-form Natural products C12CCC3C4(C)CCCC(C)(C)C4CCC3(C)C1(C)CCC1C2(C)CCC1C(=C)C HHXYJYBYNZMZKX-UHFFFAOYSA-N 0.000 description 2
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 2
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 2
- 241000321096 Adenoides Species 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- FQEQMASDZFXSJI-UHFFFAOYSA-N Anagyrin Natural products C12CCCCN2CC2C3=CC=CC(=O)N3CC1C2 FQEQMASDZFXSJI-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- CCZHKEJGAJVDRC-UHFFFAOYSA-N Belamcanidin Natural products C1=C(OC)C(OC)=CC=C1C1=COC2=CC(OC)=C(OC)C(O)=C2C1=O CCZHKEJGAJVDRC-UHFFFAOYSA-N 0.000 description 2
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 2
- GIJHDGJRTUSBJR-UHFFFAOYSA-N Bergaptol Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2O GIJHDGJRTUSBJR-UHFFFAOYSA-N 0.000 description 2
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 2
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 2
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 2
- VMEJANRODATDOF-UHFFFAOYSA-N Diphyllin Chemical compound C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C(O)=C3C=C(C(=CC3=2)OC)OC)=C1 VMEJANRODATDOF-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241001465251 Ephedra sinica Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 2
- 229920000296 Glucogallin Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 240000002045 Guettarda speciosa Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BAHUBXAYVOCLNA-UHFFFAOYSA-N Isoangelol Natural products O1C(=O)C=CC2=C1C=C(OC)C(C(OC(=O)C(C)=CC)C(O)C(C)(C)O)=C2 BAHUBXAYVOCLNA-UHFFFAOYSA-N 0.000 description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241001347978 Major minor Species 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- YAPAFDNQABLIIN-UHFFFAOYSA-N N1,N10-Dicoumaroylspermidine Natural products CC(C)=CCC1=C(O)C(CC=C(C)C)=CC(C=CC(=O)C=2C(=C(CC=C(C)C)C(O)=CC=2)O)=C1 YAPAFDNQABLIIN-UHFFFAOYSA-N 0.000 description 2
- UBAMGTKSOKGECF-UHFFFAOYSA-N Neobyakangelicol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)C(C)=C)=C1OC=CC1=C2OC UBAMGTKSOKGECF-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- QTAGQHZOLRFCBU-UHFFFAOYSA-N Oxypeucadanin Natural products CC1(C)OC1COC1=C(C=CO2)C2=CC2=C1C=CC(=O)O2 QTAGQHZOLRFCBU-UHFFFAOYSA-N 0.000 description 2
- NUCBCBCPICFGMZ-UHFFFAOYSA-N Oxypeucedanin Natural products CC1(C)OC1COC1=CC(=O)OC2=C1C=C1C=COC1=C2 NUCBCBCPICFGMZ-UHFFFAOYSA-N 0.000 description 2
- MWEVYJRFLDKUCW-UHFFFAOYSA-N Oxypeucedonin-hydrat Natural products CC(C)(O)C(O)Cc1c2C=CC(=O)Oc2cc3occc13 MWEVYJRFLDKUCW-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 229930194567 Pedatisectine Natural products 0.000 description 2
- XXARIFJTXNCWNT-UHFFFAOYSA-N Phellopterin Natural products COc1c2C=CC(=O)Oc2c(OC=CC(C)C)c3occc13 XXARIFJTXNCWNT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 244000141353 Prunus domestica Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- YAPAFDNQABLIIN-XNTDXEJSSA-N Sophoradin Chemical compound CC(C)=CCC1=C(O)C(CC=C(C)C)=CC(\C=C\C(=O)C=2C(=C(CC=C(C)C)C(O)=CC=2)O)=C1 YAPAFDNQABLIIN-XNTDXEJSSA-N 0.000 description 2
- RFAOSYMVZBUVLO-UHFFFAOYSA-N Sophoradin Natural products COC(=O)CCC1(C)C(CCC2(C)C1CCC3C(CCC23C)C(C)(O)CCC=C(C)C)C(=C)C RFAOSYMVZBUVLO-UHFFFAOYSA-N 0.000 description 2
- AIFRLZKCLIPEMC-UHFFFAOYSA-N Sophoradochromene Natural products C=1C=2C=CC(C)(C)OC=2C(CC=C(C)C)=CC=1C=CC(=O)C1=CC=C(O)C(CC=C(C)C)=C1O AIFRLZKCLIPEMC-UHFFFAOYSA-N 0.000 description 2
- 229930187719 Soyasaponin Natural products 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- VGSYCWGXBYZLLE-QEEQPWONSA-N Trifolirhizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2[C@H](C3=CC=4OCOC=4C=C3O2)CO2)C2=C1 VGSYCWGXBYZLLE-QEEQPWONSA-N 0.000 description 2
- FCRUGSNPZLERNO-UHFFFAOYSA-N Trifolirhizin Natural products OCC1OC(Oc2ccc3C4Oc5c6OCOc6ccc5C4COc3c2)C(O)C(O)C1O FCRUGSNPZLERNO-UHFFFAOYSA-N 0.000 description 2
- PLSSBWGEYMENGJ-UHFFFAOYSA-N Villoside Natural products CC1CCC2C1C(=O)OCC2COC1OC(CO)C(O)C(O)C1O PLSSBWGEYMENGJ-UHFFFAOYSA-N 0.000 description 2
- BLQBKLXDFXHPPE-UHFFFAOYSA-N Villosol Natural products COc1cc2OC(=C)C3=C(C(=O)c4c(O)cc5OC(Cc5c4O3)C(=C)C)c2cc1OC BLQBKLXDFXHPPE-UHFFFAOYSA-N 0.000 description 2
- RPOWAISXPHIEJS-UHFFFAOYSA-N Villosol+ Natural products C1OC(=O)C(C)C2CC(O)C(C)(O)C21 RPOWAISXPHIEJS-UHFFFAOYSA-N 0.000 description 2
- DBLVGADGVDUSHJ-UHFFFAOYSA-N Villosolside Natural products C12COC(=O)C(C)C2CC(O)C1(C)OC1OC(CO)C(O)C(O)C1O DBLVGADGVDUSHJ-UHFFFAOYSA-N 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- YXCORZFYRFZUOV-UHFFFAOYSA-N Xanthotoxol Natural products COc1c2OC(O)C=Cc2cc3ccoc13 YXCORZFYRFZUOV-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- YWJGYBXHXATAQY-BOTWUFHUSA-N [(3s,4ar,6ar,6as,8ar,12ar,14ar,14br)-4,4,6a,6a,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,8,9,10,12,12a,13,14,14a-tetradecahydropicen-3-yl] acetate Chemical compound C([C@H]1[C@]2(C)CC[C@H]34)C(C)(C)CC[C@]1(C)CC=C2[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C YWJGYBXHXATAQY-BOTWUFHUSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- JSNRRGGBADWTMC-UHFFFAOYSA-N alpha-farnesene Natural products CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 description 2
- FQEQMASDZFXSJI-YNEHKIRRSA-N anagyrine Chemical compound C([C@@H]12)CCCN1C[C@H]1C3=CC=CC(=O)N3C[C@H]2C1 FQEQMASDZFXSJI-YNEHKIRRSA-N 0.000 description 2
- ICFWMXKHGNCJTK-UHFFFAOYSA-N anagyrine Natural products O=C1C=CC=C2C3CC(CC4CCCCN4C3)N12 ICFWMXKHGNCJTK-UHFFFAOYSA-N 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 229930183733 angelol Natural products 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000001716 anti-fugal effect Effects 0.000 description 2
- 230000003602 anti-herpes Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- 229960002045 bergapten Drugs 0.000 description 2
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 2
- GDVRUDXLQBVIKP-UHFFFAOYSA-N beta-D-glucogallin Natural products OC1C(O)C(O)C(CO)OC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- PKRPFNXROFUNDE-UHFFFAOYSA-N biac-angelicin Natural products O1C(=O)C=CC2=C1C(OCC(O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 2
- 235000007336 cyanidin Nutrition 0.000 description 2
- 235000007242 delphinidin Nutrition 0.000 description 2
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- RFXQCUDAHXPYOF-UHFFFAOYSA-N diphyllin Natural products COc1cc2c(c3ccc4OCOc4c3)c5C(=O)OCc5c(O)c2cc1O RFXQCUDAHXPYOF-UHFFFAOYSA-N 0.000 description 2
- 229960002819 diprophylline Drugs 0.000 description 2
- HIBKFQRBONXURO-UHFFFAOYSA-N docosane-1,22-diol Chemical compound OCCCCCCCCCCCCCCCCCCCCCCO HIBKFQRBONXURO-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- KGHSLXLLBHRMML-VKISENBKSA-N glucogallin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 KGHSLXLLBHRMML-VKISENBKSA-N 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 2
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- XVARCVCWNFACQC-RKQHYHRCSA-N indican Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=CC=C12 XVARCVCWNFACQC-RKQHYHRCSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- CDYBOKJASDEORM-HBVDJMOISA-N isomangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC1=CC(O)=C(O)C=C1C2=O CDYBOKJASDEORM-HBVDJMOISA-N 0.000 description 2
- ALKWDTQJMCZSSY-UHFFFAOYSA-N isomangiferin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)c4cc(O)c(O)cc4Oc23)C(O)C(O)C1O ALKWDTQJMCZSSY-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- VGSYCWGXBYZLLE-UHFFFAOYSA-N maackiain 3-O-beta-D-galactopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2C(C3=CC=4OCOC=4C=C3O2)CO2)C2=C1 VGSYCWGXBYZLLE-UHFFFAOYSA-N 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- 229930007503 menthone Natural products 0.000 description 2
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- CULUKMPMGVXCEI-VHSXEESVSA-N n-methylcytisine Chemical class C12=CC=CC(=O)N2C[C@@H]2CN(C)C[C@H]1C2 CULUKMPMGVXCEI-VHSXEESVSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- HRWVKZXRZVVBLP-UHFFFAOYSA-N oxypeucedanin hydrate Natural products CC(C)(O)C(O)CCc1c2C=CC(=O)Oc2cc3occc13 HRWVKZXRZVVBLP-UHFFFAOYSA-N 0.000 description 2
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 2
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- KFUCYPGCMLPUMT-UHFFFAOYSA-N perlolyrine Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1NC1=CC=CC=C21 KFUCYPGCMLPUMT-UHFFFAOYSA-N 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000013138 pruning Methods 0.000 description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
- 229960003908 pseudoephedrine Drugs 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- YLZYAUCOYZKLMA-SJCJKPOMSA-N pterocarpin Chemical compound O1C2=CC=3OCOC=3C=C2[C@H]2[C@@H]1C1=CC=C(OC)C=C1OC2 YLZYAUCOYZKLMA-SJCJKPOMSA-N 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- IORSRBKNYXPSDO-NDEPHWFRSA-N sophoranone Chemical compound CC(C)=CCC1=C(O)C(CC=C(C)C)=CC([C@H]2OC3=C(CC=C(C)C)C(O)=CC=C3C(=O)C2)=C1 IORSRBKNYXPSDO-NDEPHWFRSA-N 0.000 description 2
- QZVQYTIOGPCCRU-JOCHJYFZSA-N sophoranone Natural products COc1c(O)c(OC)c(cc1CC=C(C)C)[C@]2(O)COc3cc(O)cc(O)c3C2=O QZVQYTIOGPCCRU-JOCHJYFZSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 2
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 2
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 description 2
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000002978 thoracic duct Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 230000007888 toxin activity Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- JWVYQQGERKEAHW-UHFFFAOYSA-N xanthotoxol Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2O JWVYQQGERKEAHW-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- VPDZRSSKICPUEY-GQRSATBHSA-N (+)-Bicyclogermacrene Natural products CC1(C)[C@@H]/2[C@H]1CC/C(/C)=C\CC/C(/C)=C\2 VPDZRSSKICPUEY-GQRSATBHSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 description 1
- HSGPAWIMHOPPDA-SFYZADRCSA-N (-)-Cleroindicin F Natural products C1C(=O)C=C[C@@]2(O)[C@@H]1OCC2 HSGPAWIMHOPPDA-SFYZADRCSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- ZVXWFPTVHBWJOU-AWQYILTISA-N (1s,4as,5r,7as)-5-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C(C(O)=O)=CO1 ZVXWFPTVHBWJOU-AWQYILTISA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical class O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LKUWQWDAIWXHIY-CHNJZELVSA-N (z)-2-methylbut-2-enoic acid Chemical compound C\C=C(\C)C(O)=O.C\C=C(\C)C(O)=O LKUWQWDAIWXHIY-CHNJZELVSA-N 0.000 description 1
- BUCJHJXFXUZJHL-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol Chemical class CCC1(O)CCCCC1 BUCJHJXFXUZJHL-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MBDOYVRWFFCFHM-SNAWJCMRSA-N 2-Hexenal Natural products CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-M 2-Methyl-2-butenoic acid Natural products C\C=C(\C)C([O-])=O UIERETOOQGIECD-ARJAWSKDSA-M 0.000 description 1
- OMAMGHBETNHQJC-KDURUIRLSA-N 2-[(2r,6s)-6-phenacylpiperidin-2-yl]-1-phenylethanone Chemical compound C([C@@H]1CCC[C@@H](N1)CC(=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 OMAMGHBETNHQJC-KDURUIRLSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- BVMOMQJYQYBMKL-GFCCVEGCSA-N 4-[(2s)-2-hydroxy-3-methylbut-3-enoxy]furo[3,2-g]chromen-7-one Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC[C@@H](O)C(=C)C BVMOMQJYQYBMKL-GFCCVEGCSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- NHFRGTVSKOPUBK-UHFFFAOYSA-N 4-phenylbutanal Chemical compound O=CCCCC1=CC=CC=C1 NHFRGTVSKOPUBK-UHFFFAOYSA-N 0.000 description 1
- OOCLVMCVOWKECB-UHFFFAOYSA-N 6,6-dimethylbicyclo[3.1.1]heptane-4-carbaldehyde Chemical compound C1C2C(C)(C)C1CCC2C=O OOCLVMCVOWKECB-UHFFFAOYSA-N 0.000 description 1
- KMRMUZKLFIEVAO-UHFFFAOYSA-N 7,7-dimethylbicyclo[3.1.1]hept-3-ene-4-carbaldehyde Chemical compound C1C2C(C)(C)C1CC=C2C=O KMRMUZKLFIEVAO-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- WOELDRZIQLRDQB-UHFFFAOYSA-N 9-(1,3-benzodioxol-5-yl)-5-methoxy-8h-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one Chemical compound C12=CC=3OCOC=3C=C2C(OC)=C(C(=O)OC2)C2=C1C1=CC=C(OCO2)C2=C1 WOELDRZIQLRDQB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000906579 Actaea cimicifuga Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241001521511 Albizia kalkora Species 0.000 description 1
- 235000018645 Allium odorum Nutrition 0.000 description 1
- 240000008654 Allium ramosum Species 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000317400 Arisaema heterophyllum Species 0.000 description 1
- DGDWCRWJRNMRKX-DILZHRMZSA-N Asperulosidic acid Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@@H](O)C=C2COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGDWCRWJRNMRKX-DILZHRMZSA-N 0.000 description 1
- DGDWCRWJRNMRKX-UHFFFAOYSA-N Asperulosidinsaeure Natural products CC(=O)OCC1=CC(O)C(C(=CO2)C(O)=O)C1C2OC1OC(CO)C(O)C(O)C1O DGDWCRWJRNMRKX-UHFFFAOYSA-N 0.000 description 1
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000596154 Belamcanda Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- ORBITTMJKIGFNH-LLVKDONJSA-N Byakangelicol Chemical compound C1=2OC(=O)C=CC=2C(OC)=C2C=COC2=C1OC[C@H]1OC1(C)C ORBITTMJKIGFNH-LLVKDONJSA-N 0.000 description 1
- HFEYMQSAJXTNIH-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O HFEYMQSAJXTNIH-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- NNDOCYLWULORAM-UHFFFAOYSA-N Cnidilin Chemical compound C1=CC(=O)OC2=C1C(OCC=C(C)C)=C1C=COC1=C2OC NNDOCYLWULORAM-UHFFFAOYSA-N 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- VKWWRUZYBNTDHM-AXECJBQYSA-N Deacetylasperulosidic acid Natural products OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O VKWWRUZYBNTDHM-AXECJBQYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 241000897928 Echinops latifolius Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930186482 Eupachifolin Natural products 0.000 description 1
- 241001478385 Eupatorium japonicum Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- JSKCJJNYSGWZDU-RQJSCMEKSA-N Gardoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(=C)[C@@H](O)C[C@@H]2C(C(O)=O)=CO1 JSKCJJNYSGWZDU-RQJSCMEKSA-N 0.000 description 1
- JSKCJJNYSGWZDU-PKPQBBKFSA-N Gardoside Natural products O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(=C)[C@@H](O)C2 JSKCJJNYSGWZDU-PKPQBBKFSA-N 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 241001113926 Gelsemium Species 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 241000208278 Hyoscyamus Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- OMAMGHBETNHQJC-UHFFFAOYSA-N Isolobelanine Natural products C=1C=CC=CC=1C(=O)CC(N1)CCCC1CC(=O)C1=CC=CC=C1 OMAMGHBETNHQJC-UHFFFAOYSA-N 0.000 description 1
- 244000003187 Juncus effusus Species 0.000 description 1
- 244000308415 Justicia procumbens Species 0.000 description 1
- XAMCMRHCZWDKAS-UHFFFAOYSA-N L-Prolyl-L-valine anhydride Natural products CC(C)C1NC(=O)C2(C)CCCN2C1=O XAMCMRHCZWDKAS-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000486990 Lemmaphyllum carnosum var. microphyllum Species 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- IDEMKXUAULKYJV-BGYRXZFFSA-N Lobelanine Chemical compound C([C@@H]1N([C@@H](CCC1)CC(=O)C=1C=CC=CC=1)C)C(=O)C1=CC=CC=C1 IDEMKXUAULKYJV-BGYRXZFFSA-N 0.000 description 1
- IDEMKXUAULKYJV-UHFFFAOYSA-N Lobelanine Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(=O)C1=CC=CC=C1 IDEMKXUAULKYJV-UHFFFAOYSA-N 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000030984 MIRAGE syndrome Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- KMRMUZKLFIEVAO-RKDXNWHRSA-N Myrtenal Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2C=O KMRMUZKLFIEVAO-RKDXNWHRSA-N 0.000 description 1
- 229930192770 Neojusticin Natural products 0.000 description 1
- YLZYAUCOYZKLMA-UHFFFAOYSA-N O-Methyl-maackiain Natural products O1C2=CC=3OCOC=3C=C2C2C1C1=CC=C(OC)C=C1OC2 YLZYAUCOYZKLMA-UHFFFAOYSA-N 0.000 description 1
- RINSJDWDXSWUOK-UHFFFAOYSA-N OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 Chemical compound OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 RINSJDWDXSWUOK-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- USNDBWMOOJYKBW-UHFFFAOYSA-N Pabulenol Natural products CC(=C)C(O)COc1c2C=CC(=O)Oc2c(O)c3occc13 USNDBWMOOJYKBW-UHFFFAOYSA-N 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000148137 Patrinia villosa Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- BMLZFLQMBMYVHG-UHFFFAOYSA-N Phellopterin Chemical compound O1C(=O)C=CC2=C1C(OCC=C(C)C)=C1OC=CC1=C2OC BMLZFLQMBMYVHG-UHFFFAOYSA-N 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 240000000432 Pistacia chinensis Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241001646828 Platostoma chinense Species 0.000 description 1
- 244000086956 Polygonum perfoliatum Species 0.000 description 1
- PXCOYCUFJMMDCP-UHFFFAOYSA-N Ponasteron C Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CC(O)C(C)C)CCC33O)C)C3=CC(=O)C21O PXCOYCUFJMMDCP-UHFFFAOYSA-N 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- SLEPYIDGMPDTFO-UHFFFAOYSA-N Pterocarpin Natural products COc1ccc2C3Oc4c5OCOc5ccc4C3COc2c1 SLEPYIDGMPDTFO-UHFFFAOYSA-N 0.000 description 1
- UMMBJCYNGLCGEF-ATDZVSDASA-N Pterosterone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)C[C@@H](O)C(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UMMBJCYNGLCGEF-ATDZVSDASA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241001237996 Pyrrosia sheareri Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical class C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- IAXBXCJUSPUULA-AQXOCQMTSA-N Suspensaside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](O)c2cc(O)c(O)cc2)O[C@H]1CO[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1)/C=C/c1cc(O)c(O)cc1 IAXBXCJUSPUULA-AQXOCQMTSA-N 0.000 description 1
- UZXMLGUMBQQVME-UHFFFAOYSA-N Swietenocoumarin B Natural products O1C(=O)C=CC2=C1C(CC=C(C)C)=C1OC=CC1=C2OC UZXMLGUMBQQVME-UHFFFAOYSA-N 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- YWJGYBXHXATAQY-UHFFFAOYSA-N Taraxerylacetat Natural products C12CCC3(C)C4CC(C)(C)CCC4(C)CC=C3C1(C)CCC1C2(C)CCC(OC(=O)C)C1(C)C YWJGYBXHXATAQY-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
- MUCRYNWJQNHDJH-UHFFFAOYSA-N Ursonic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C MUCRYNWJQNHDJH-UHFFFAOYSA-N 0.000 description 1
- 241000510764 Villosa Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- IAXBXCJUSPUULA-RHTWPPHESA-N [(2r,3s,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-hydroxyethoxy]-4,5-dihydroxy-2-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCC(O)C=2C=C(O)C(O)=CC=2)O1 IAXBXCJUSPUULA-RHTWPPHESA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 description 1
- AHFAQKUDQUDLNP-AGUBZPQCSA-N asperulosidic acid Natural products CC(=O)OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O AHFAQKUDQUDLNP-AGUBZPQCSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- VPDZRSSKICPUEY-JEPMYXAXSA-N bicyclogermacrene Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@@H]2C(C)(C)[C@H]12 VPDZRSSKICPUEY-JEPMYXAXSA-N 0.000 description 1
- RXARZHLXLNWPFG-UHFFFAOYSA-N bicyclogermacrene Natural products CC1=C2C3C(CCC2=CCC1)C3(C)C RXARZHLXLNWPFG-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- MAEVSPLUELJOMM-UHFFFAOYSA-N caffeic acid methyl ester Natural products COC(=O)C=CC1=CC=C(O)C=C1O MAEVSPLUELJOMM-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- WACBUPFEGWUGPB-MIUGBVLSSA-N calycosin-7-O-beta-D-glucoside Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O WACBUPFEGWUGPB-MIUGBVLSSA-N 0.000 description 1
- WACBUPFEGWUGPB-UHFFFAOYSA-N calycosin-7-O-beta-D-glucoside Natural products C1=C(O)C(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O WACBUPFEGWUGPB-UHFFFAOYSA-N 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- KXBQYMQMSNZAKO-UHFFFAOYSA-N canthin-6-one Natural products C12=CC=CC=C2N2C(=O)CCC3=NC=CC1=C32 KXBQYMQMSNZAKO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- HSGPAWIMHOPPDA-UHFFFAOYSA-N cleroindicin F Natural products C1C(=O)C=CC2(O)C1OCC2 HSGPAWIMHOPPDA-UHFFFAOYSA-N 0.000 description 1
- 239000009733 cnidilin Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MGRRGKWPEVFJSH-UHFFFAOYSA-N dianthrone Natural products C12=CC=CC=C2C(=O)C2=CC=CC=C2C1=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MGRRGKWPEVFJSH-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- WLGSIWNFEGRXDF-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O.CCCCCCCCCCCC(O)=O WLGSIWNFEGRXDF-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000008669 duhuo Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229930190724 eupasimplicin Natural products 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- FRBORWNVTCITAQ-UHFFFAOYSA-N ferulin Natural products C1=C2C(C)=CC(=O)C2=C(C)CC2OC(=O)C(C)C21 FRBORWNVTCITAQ-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- YDLBHMSVYMFOMI-SDFJSLCBSA-N germacrene Chemical compound CC(C)[C@H]1CC\C(C)=C\CC\C(C)=C\C1 YDLBHMSVYMFOMI-SDFJSLCBSA-N 0.000 description 1
- 229930001612 germacrene Natural products 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Natural products C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 1
- XVARCVCWNFACQC-UHFFFAOYSA-N indoxyl-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CNC2=CC=CC=C12 XVARCVCWNFACQC-UHFFFAOYSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- LDHQCZJRKDOVOX-IHWYPQMZSA-N isocrotonic acid Chemical compound C\C=C/C(O)=O LDHQCZJRKDOVOX-IHWYPQMZSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 125000000396 limonene group Chemical group 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- OPMNROCQHKJDAQ-FKSUSPILSA-N loline Chemical class C1C[C@@H]2O[C@H]3[C@H](NC)[C@@H]2N1C3 OPMNROCQHKJDAQ-FKSUSPILSA-N 0.000 description 1
- 150000002646 long chain fatty acid esters Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- OCNYGKNIVPVPPX-HWKANZROSA-N methyl caffeate Chemical compound COC(=O)\C=C\C1=CC=C(O)C(O)=C1 OCNYGKNIVPVPPX-HWKANZROSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 201000001705 nipple carcinoma Diseases 0.000 description 1
- WPBWJEYRHXACLR-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O.OC(=O)CCCCCCCC(O)=O WPBWJEYRHXACLR-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- TWHMVKPVFOOAMY-UHFFFAOYSA-N octanedioic acid Chemical compound OC(=O)CCCCCCC(O)=O.OC(=O)CCCCCCC(O)=O TWHMVKPVFOOAMY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000000955 oleanolic acid group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- BVMOMQJYQYBMKL-UHFFFAOYSA-N pangelin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC(O)C(=C)C BVMOMQJYQYBMKL-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- UMMBJCYNGLCGEF-OAUIFJKNSA-N pterosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)C[C@H](O)C(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UMMBJCYNGLCGEF-OAUIFJKNSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 239000009728 shiwei Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- COBXDAOIDYGHGK-UHFFFAOYSA-N syringaldehyde Natural products COC1=CC=C(C=O)C(OC)=C1O COBXDAOIDYGHGK-UHFFFAOYSA-N 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- PMOWTIHVNWZYFI-AATRIKPKSA-N trans-2-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1O PMOWTIHVNWZYFI-AATRIKPKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 229930191012 ziyuglycoside Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗淋巴结关系型癌症的中药,是依据疗法分类,排除上消化道过敏型及肝、胰脏内本体型所余的淋巴结关系型,它包含了较多的癌种别。此中药包括了党参、黄芪、薏苡仁、山佩兰、橘皮、爵床、夏枯草、凉粉草、栀子、连翘、赤芍、大黄、虫、白花蛇舌草、扛板归、山豆根、木槿皮、天南星、半边莲、白蔹、漏芦、石苇、乳香、没药、蚤休、败酱、白芷、射干、蒲公英、螺厣草、皂荚、独活、麻黄、升麻等药物。并且采用具有治癌效益的茯苓粉为赋形剂。
Description
技术领域
本发明涉及一种中药,尤其是指一种治疗淋巴结关系型癌症的中药。
背景技术
具有一定疗效的治癌内服药迟迟未见产销,癌症的医疗仍停滞在抗癌的泥淖里;在存疑的抗、杀、灭前提下,权宜性的血管栓塞、放射电疗、化学药物滴注等疗法,却被误认为常规;因为它的粗浅以及忽略了病患的整体病理,致使疗效困守低限,且在繁杂、极端、刚猛的疗程内,令患者产生煎熬、难耐的痛苦,尤其是剂量依赖、恶劣的过敏反应、增进转移等等。
由于商业利益及诸多原因的困扰,癌症的研究一直被框束在一定模式里,抗癌就是治癌的观念广被宣传,且深植人心,而事实上,所有动听的理论在未达目标之前,应属于假设,难达目标的假设性理论,必然存在瑕疵、疑问;故在癌症的治疗研究方面,突破一定模式,提出新的创见、理论、疗法,实系迫切的需要,但先前提出的创见、理论等,因缺少医疗根据,脱离了基本的、实际的,故言虽美妙,却是虚幻的海市蜃楼而已。
生物科技、癌药研发等等专家,若无治癌的临床经验,而在仅知癌细胞,而不知癌环境、癌变化等等繁琐问题,亦只能研发抗癌药以对付癌细胞,但它与治癌的实践仍有甚远的距离。
癌的的组织、结构、形态,以及癌位置的研究均属重要,先前均以此或机体系统予以分类;但就治癌的实践层次言之,这种分类法并不等合治癌的目的与施展效益,须再进一步予以类型机理的分类。
中国的中医资源丰沛,近年来有关抗癌、治癌的研究颇有进展,且不乏治癌内服药通过国内的申请、公开发表,但其特征均表现在药物与制备方式上,在阐述固有中医治癌的辨证论治外,仍然不能跳脱抗癌即是治癌的窠臼;缺乏创见与新论据,且不能释明用词的定义,也许由此原因,至今并不见有产业利用者。
发明内容
本发明的主要目的,在于提供一种治疗淋巴结关系型癌症的中药,具有更好的治癌效果,开拓中医药治癌的新途径。
缘为达成本发明的上述目的,特为提供相关著作、附件,并将本发明的创新理论、治疗分类、类型机理、药物组配、临床试验以及效率统计、癌种转移统计等,阐述如下。
创新理论
旧有抗癌理论的实践,并不能突破瓶颈,提升有效率,因此发明人创立了变易癌环境的新疗法,该连贯性新理论依序是:物的生、壮、老、死论,物势形成环境论,癌的周环病理论,六大要素的癌病理与论治,以及癌的类型机理论中的癌种转移论等等;凡此新理论,皆固有中华医药论据的延伸与创革,它的特征是融入哲学理念,应用了中国古代哲学家老子、李聃(约在公元前580年)的著述,依据自然的物理现象与规则,抉发出与治癌相关的论述。
首先,物的生、壮、老、死论(参阅发明人著作权登记证书号2001-A-0342廿一世纪癌症治疗新道路、第二章前段),在于说明,凡是能够繁衍同类后代的物体,是为自生物,也就是现代所称的生物;生物皆不可能长生不老,其正常的生态必然要有出生(繁衍)、茁壮、老弱、病亡的过程;癌细胞亦会在机体内消失。
为了达成上述假设方法,就必要先行了解癌细胞生、壮、老、死的实况,尤其是病体环境中、变易的过程与原因;从此而再涉及了物势形成环境论(参阅发明人著作权登记证书号2001-A-0342廿一世纪癌症治疗新道路第二章后段)。在此理论中,将可发觉生物生存的一种共通性,那就是:生物的生存,在它各类、纲、科、属的关联中,皆有各自的,一定的环境适应程度,此环境适应程度与物的生、壮、老、死有了密切关系,在舒适的程度内则繁衍、茁壮,而在厌恶的环境中则能促使老弱、败亡。在本论中,另有更珍贵的发现,那就是:环境的形成,可因加入物质的性情、姿态、导向(物势)而决定;譬如,正常的人体环境内,原不适合于癌细胞的生存、活动;但当人体长期加入、感受、或承接了异常物质,因它的性情、姿态、导向在体内变易了原有环境,才逐渐形成适合于癌细胞的生存、活动,癌细胞于是繁衍、茁壮,此乃罹癌的哲理。
值得庆幸的是,药物也是一种物质,尤其是拥有8000品类以上的中草药,自古传记述,以及现代研析中可知它鲜明的物势,包括了质地、气、味、成分等,也就是综合性的药理作用;只要了解癌环境的实况,再选择适当的药物、慎重组合、再予以服食,当然可以藉药物的性情、姿态、导向、在癌患体内形成另一环境,变易为令癌细胞难以适应,倍觉厌恶的环境,则繁衍、茁壮受挫、老弱、败亡增进,则癌症可治。
适宜于癌细胞生存、繁衍、茁壮的环境,已显然异于正常人体内素质,称为癌的特殊体质,经长期临床、研讨而已能掌握它的病理现象,它就是癌的周环病理论(参阅发明人著作权登记证书号2001-A-0342廿一世纪癌症治疗新道路第三章及附录4)。它是所有癌患体内必然存在的,其固定性周环病理分别为(1)胰腺功能低落,与他器官的联系性不良;(2)肝脏、门静脉、脾脏内的通透障碍,常呈现高压病象;(3)防御组织、淋巴循环功能衰退、障碍。此三种病理所呈现的环境,就是癌细胞感觉舒适的环境。
凡所有一切生物,皆由动能、空隙、实体、湿度、气流、温度等六种要素所组成,是谓:六大组成论,人类机体亦无例外(参阅附件二,发明人著作的中医药的锁与钥、第一篇第五章),六大缺一即告死亡;在人体生理、机能的六大之间,且存有一定限度的配合与运作,超越限度者必然产生病态;癌症研究、治疗的精微处,应该是切实的了解癌环境中六大要素的变化与异常,并采取适宜治法,此即六大要素的癌病理与论治(参阅附件二,发明人著作的中医药的锁与钥第二篇第七章)。
癌的分类形式颇多,有以癌的组织、结构、形态,或以所在位置、系统而分类者;为了治疗的施展与效益,发明人乃深入探讨各类癌种的关系,以及致病机理的同、异,依据所得的类型机理而分为三大类型(见后)。癌的转移、扩散殊属重要,它与化、放疗后的关系颇深,但先前甚少此种记述、更乏定论;从此类型机理而可了解新创见的癌种转移论,可知所以转移、扩散的原因,并经癌种动态统计而得到证实。
治疗分类
癌瘤是属于上皮性的肿瘤,其主要的发生部位是皮肤(颜面、头及四肢等);粘膜(口腔、食道、胃、肠、子宫等);腺体脏器(乳房、肝、肾、肺等)。并不原发于无上皮性的骨、肌肉、结缔组织及神经系统等处。依组织种类,它可分为1.表皮癌或扁平细胞癌,2.单纯性癌或腺细胞癌或骰子形细胞癌或单纯性充实性癌,3.腺癌或圆柱细胞癌,4.胶样癌及粘液癌。若依据临床的性状,又可分为1.皮肤癌瘤,包括扁平皮肤癌、深蚀性癌、乳头性癌,多发生于颜面、头、项、胸、脐、外阴、四肢等处。2.粘膜的癌瘤,包括上皮性粘膜、圆柱上皮性粘膜,前者多发生于口唇、口腔、上颚窦、食道、阴道、阴茎等处,后者发生于胃、肠、及胆囊等处。3.实质性脏器的癌瘤,发生于乳房、肝、肾、胰、卵巢、子宫、摄护腺、甲状腺、睾丸等处。
所有关系癌症的病理解剖、症候等等信息,均是癌研者所须知,然而,由于抗癌方针的存疑,以及原病历的短缺,加上疗效低迷的事实,先前所有究竟未能尽为凭据,而必要予以新的创革;例如1950年代的多数医学教科书,对于肺癌的原发状况谓:其由肺泡上皮、支气管上皮、支气管腺上皮而特发者甚少。且指肺癌多数是他种癌转移而来;但据发明人临床所统计,由肺内腺皮特发者占多数,至于由肺转移他处者,多数仍保留有肺癌的原有症候。以本案17位肺癌患者计的,原发者有11人,转入而发者6人,原发肺癌再转移肝、淋巴、骨者5人且保留有肺癌症候。
在癌症分类方面,本发明依各类型癌的特殊性情,致病机理的同、异,各癌种的相互关系等等,即以癌的类型机理而分类,此种分类的特征,是在于治疗用药的真实性与效率;此乃有鉴于过去的治癌药物,多概括于某系统中,如某复方针对了消化系统的癌症,包括了食道、胃、贲门、肝、胰、胆、肠等癌;但就发明人治癌经验来说,实觉有窒滞难行之处。
食道、胃、幽门、贲门属于神经敏感的部位,当它发生癌瘤时,因过敏而必有呕吐、反食、上逆的反应,加上癌肿粒的发炎现象而有阻塞、疼痛不堪的症候,类此紧迫性病象若无法先予平伏,则药物难以通过,癌药不得发挥作用,更何况此等癌肿粒另有特殊性情,岂能与肝、胰癌同用一药物?肝、胰虽是消化器官,但肝却掌管了机体的化学、改毒重任,胰腺的内、外分泌亦是机体的重要司命;且肝、胰癌多发生于脏器内部,具有特殊性情是必然的。肠部亦是消化器官,但据发明人深入研究,它与肠淋巴总结(培氏斑)、肠骨淋巴均有重大、密切关系,依据1950年代的病理解剖证实:原发性肠癌的种类,除少见肝门扁平上皮癌外,悉由Lieberkulms氏腺底的腺上皮、发生圆柱性上皮癌;腺癌最多,髓样癌、胶样癌、硬性癌、依序次的。由此可知肠癌与淋巴腺的紧密关连性,且与上述二种的治疗分类难以混同。
综合上述,是以依癌的类型机理,分成三类:1、是为上消化道敏感型;2、是肝、胰脏内本体型;3、是为淋巴结关系型,亦即本发明的广泛性癌类型;以此而分类,将有利于用药处治的施展与效率。
类型机理
癌症原发、或转移于人体不同的器官、组织内,而有各别的癌名;为了治疗策略、用药处治的方便与效益,必须逐项研讨、探测其病机、病理,且以病机、病理的是否雷同、密切关联,而作为类型分判的依据,准此类型而分别配方用药施治的,庶可方医药产品的利用、顾全疗效的确实与提升。
发明人乃准此原则,将众多癌瘤分为、上消化道过敏型、肝胰脏内本体型、淋巴结关系型等三大类型;本发明案的广泛性、即指包括了较多癌种的淋巴结关系型。淋巴结关系型的定义,是指此类型的所有癌种别,均与淋巴结以及淋巴系统存在了直接、密切的关系;为使理解,兹将本型的类型机理概述如下:
上腔及头、颈项等处癌种别,与上颚窦、咽、舌、扁桃体、颔下、颈、锁骨、胸肺腺、腋下等淋巴结,发生密切关系,上述淋巴相距甚近,功能相互影响,故本处原发的癌平向、相互转移的机率甚高;这些淋巴的循环,均于锁骨下静脉角转入血液循环里,缺乏下向的淋巴管道,因而上部癌在正常情况时,下移的机率较低。
下腹腔、肾、骨等等下部癌种别,均与乳糜池、肠骨、培氏斑、鼠蹊等淋巴结,以及邻近淋巴系统发生密切关系,此等淋巴结相距甚近,功能直接影响,故原发本处的癌,平向、相互转移的机率亦高。但下腹腔内的器官附近,遍布了网状微淋巴管,在逐渐集结后,汇合于乳糜池,即循淋巴导管而上升;在它注入锁骨下主静脉的先,癌细胞随著淋巴液上移,接触了淋巴结,当此淋巴结功能不能胜任时,就形成了下腔癌向上转移的机理,因而下腔癌向上转移的机率特高,亦有转移入肝脏者,则是经由门静脉所致。
癌的转移机率,因上述原因而平移、同部转移者多,下腔癌上移者多,唯有上腔癌下移的机率特低;但事实上仍不乏有上焦癌种下移者,经过统计发觉,此异常现像是化、放疗所促进的;当上腔、头、项、胸、乳部接受剧烈性的化、放疗时,机体的器官、组织因是附著物而难逃酷刑,但残害性、游击性的癌细胞却是狡兔三窟,自有选避舒适环境的天性,逢剧变发生则逃避到最远程的下腹腔,且多数选择在缺乏淋巴管的臀、腿、腰脊骨内;此就是化、放疗后多数下移的机理。
经过统计而得下列综合结论:A上焦(上腔与头项部)癌种向下转移能度甚低,且低于本位的平转、上移。B上焦癌经化、放疗者,转移能度增加3.5倍,向下转移能度增加14.5倍。C下焦(下腹腔、肾、足部)癌在不经化、放疗状况下,向上转移是上焦癌向下转移的8倍,因下焦癌本就有向上转移的高能度,故经化、放疗后,转上的影响较少(请参阅癌种转移统计)。
自上面统计所结果,足可证实此淋巴结关系型的广泛性癌种别与淋巴结、淋巴循环之间,不但关系密切,且其功能、运作均有直接的影响;是以遵循妥善策略,选择适当药物以药物各别或组合的药理作用,即以其物势而改变上、下腔淋巴结、淋巴循环的异常环境,促使癌细胞产生厌恶感受,就是本发明案药物组成的要件之一。
根据上面的论述,本发明公开了一种治疗淋巴结关系型癌症的中药,是依据疗法分类,排除上消化道过敏型及肝、胰脏内本体型所余的淋巴结关系型,因它包含了较多的癌种别,故称的为广泛性。
此中药包括了党参、黄芪、薏苡仁、山佩兰、橘皮、爵床、夏枯草、凉粉草、栀子、连翘、赤芍、大黄、虫、白花蛇舌草、扛板归、山豆根、木槿皮、天南星、半边莲、白蔹、漏芦、石苇、乳香、没药、蚤休、败酱、白芷、射干、蒲公英、螺厣草、皂荚、独活、麻黄、升麻等药物。并且改良旧有萃取方法,以及采用具有治癌效益的茯苓粉为赋形药等特征。
本中药的选配,是依据创新的、连贯性的治癌新发现、新理论,而在变易癌环境的主旨下所完成的;它摒弃了抗、杀、灭癌细胞的旧理念与疗法,而在中医药固有理论的基础上,把握上列药物潜在的性情、姿态、导向,使之转变癌患体内癌细胞的生存环境,制造癌细胞对其环境不适、厌恶的感受,换言之,是以药物的药理变化癌环境的方法,达成治癌的目标;这种比较精致的、理性的、科学的新方法,对于原发性、转移性的肺癌、淋巴癌、鼻咽癌、肠癌、膀胱癌、宫巢癌、骨癌等等广泛性淋巴结关系型癌症,经过临床试验证实,均能得到比较理想的疗效。
药物组配
一种治疗淋巴结关系型癌症的中药,其是以下列经浓缩萃取的药粉及比例所调配组成;其中茯苓为赋形的粉剂,成分及含量已包含在各药物中。
1. | 茯苓 | 13. | 大黄 | 25. | 没药 |
2. | 党参 | 14. | 虫 | 26. | 蚤休 |
3. | 黄芪 | 15. | 白花蛇舌草 | 27. | 败酱 |
4. | 薏苡仁 | 16. | 扛板归 | 28. | 白芷 |
5. | 山佩兰 | 17. | 山豆根 | 29. | 射干 |
6. | 橘皮 | 18. | 木槿皮 | 30. | 蒲公英 |
7. | 爵床 | 19. | 天南星 | 31. | 螺厣草 |
8. | 夏枯草 | 20. | 半边莲 | 32. | 皂荚 |
9. | 凉粉草 | 21. | 白蔹 | 33. | 独活 |
10. | 栀子 | 22. | 漏芦 | 34. | 麻黄 |
11. | 连翘 | 23. | 石苇 | 35. | 升麻 |
12. | 赤芍 | 24. | 乳香 |
上述各药物中,茯苓为赋形的粉剂,其他各药物的配比为1.94%-3.94%,并可依癌患体病理的微异而取舍药物或酌以增减其比例,其最佳配比为各药物的配比均为2.941%,共计100%。
药理说明
各药物条下的药理说明,是以改善周环病理的三项病象,亦即增进胰腺功能,及与各器官的连系,排除门静脉、肝、脾内的通透障碍,平降门脉压,改善防御功能、淋巴循环、提高免疫力三大重点;以及通透淋巴结、及其它必要作用、等四项药理而分类。但中药多存在复性的药理,而非单一,有包罗上列数种作用的,故仅以权宜配置,再于(药物说明资料表)中另加以论述。
一、增进胰腺功能及与各器官的联系:
茯苓-补充营养、促进胰腺功能、增强免疫功能、安定神经系统、调整心律及机体的水分代谢。现代药理,增强正常及荷瘤小鼠的免疫功能,提高巨噬细胞的吞噬能力,对鼻咽癌、胃癌、宫颈癌等多种癌症有正面效益。在本系列治癌发明中,以其代替旧有玉米、小麦等淀粉赋形药;凡各种浓缩萃取的药液,除部分以原药未收搅、干燥外,其余均用纯茯苓未收搅赋形,以增强治癌效力。
党参-补充营养、增进胰腺、肺脏功能,改善腺体素质与分泌。现代药理试验证实,有增强机体应激能力、免疫功能、延缓衰老,抗溃疡的作用;在血液、造血功能、心血管、抗肿瘤等方面,均有正面效用,可减轻肝的脂肪变性,改善肝坏死,抑制肝淋巴间隙及中央静脉下,胶原纤维的形成。在本复方中,兼用以调和胰与各器官的联系。
黄芪-补充营养、微量元量、增强体力、增进淋巴导管上升动能、调节自律神经、防止汗腺异常过敏。调节机体水分代谢、利尿;改善淋巴体质、补充防御细胞养分。现代药理研究证实,对免疫系统有良性影响,对机体代谢、心血管系统有帮助;并有抗病毒、抗癌的作用。
薏苡仁-补充营养、健全胰腺功能,改善器官,尤其是胰腺水分代谢障碍、清除肌肉、关节、韧膜内异常物质、消炎、排脓。现代药理实验发现,有抑制骨胳肌改缩、降血糖、解热、抗炎、扩张肺血管等作用;显著增加健康人末梢血单核细胞产生抗体,增强体液免疫与抗肿瘤作用。
山佩兰-安定胰、胃、脾功能,增强人体抵抗天气暑热、耐能,发汗、解热;促进局部组织水分代谢、与血液循环,解除体内毒素。现代药理实验发现,具有抗宫颈鳞癌的作用。本复方用以加强下腹腔内器官的通透性。
橘皮-调整胰、胃功能,缓和上消化道过敏,增进食欲,祛除组织内稠粘物质,缓和气管、支气管过敏;因其有稀释稠粘物的功能,间接促进组织液、淋巴液的新陈代谢以及器官的微循环。
二、排除门静脉、肝、脾内的通透、障碍,平降门脉压:
爵床-调降体内偏高温度,促进组织水分代谢;杀灭肝内细菌、微生物、排除肝内异质的障碍;帮助消化道蠕动、镇痛、消炎。现代临床研究发现、爵床有治疗疟疾、泌尿系感染、结核性肛篓等效能。本复方用以调降门脉压,并处理肠部的偏高温度与淋巴循环。
夏枯草-清除肝血窦、门脉管壁、脾腺的异质障碍、通透肝循环、调降门脉压。通透淋巴腺、消除其发炎、肿硬病象。现代药理试验证实,有显著的降血压作用。临床研究、治疗黄疸型肝炎、肺结核有效。
凉粉草-解除因天气暑热引起的人体不适与病候;补充血液中阴柔元素、清除机体内激进成分,而有解毒、止渴、清凉消炎的功效。可治疗高血压、糖尿病、民间用治性病感染的骨内疼痛。本复方用以平降门脉压,改变癌环境的偏高温度,排除激进毒素。
栀子-清除血液中激进元素,调降偏高温度;促进机体水分代谢,清凉、利胆、解热毒,平降门脉高压,疏通肝胆,消除癌的发炎环境。
连翘-解热、消炎、解毒、利尿、通透淋巴、消除淋巴结的肿硬病象。现代药理实验,连翘有广效的抗微生物作用;有抗炎、抗肝损伤的效能,能强化末梢血管的强韧度,预防出血。本复方用作清凉降压,改善变易的癌环境。
赤芍-解热、平降血液温度、排除血栓、促进血液循环。现代药理实验,有抗血栓形成,抗血小板聚集,降血脂和动脉硬化,抗肿瘤、保肝、改善血液循环的作用。
大黄—保肝、利胆、抗胃及十二指肠溃疡;阻止结肠内水分吸收、加快内容物排出而有导泻作用。有抗菌、抗病毒、抗真菌作用。当其疏导、排出体内有害物质时,可缓解门静脉的高压。
虫-抗凝血,解除血管中血栓,具有直接扩张血管作用。疏通小动脉、微血管的循环、缓解血栓;配合他药于微循环中带出败亡癌细胞或有害物质。
三、改善防御功能、淋巴循环、提高免疫力:
白花蛇舌草-清除激进元素引发的体内偏高温度,解毒;促进局部组织,尤其是下腹腔内器官的体液代谢。现代药理试验,有增强白细胞吞噬能力,提高免疫力功能,以及抗菌、抗肿瘤的作用。对于胃癌、直肠癌有一定疗效。
扛板归-促进机体水分代谢,利尿、消肿、解热,排除组织内血栓、毒素,民间用以治疗性病感染的疾患,以及腹水症。现代药理实验,发现有抗菌、抗病毒、抗肿瘤等作用。
山豆根-清除体内激进元素(退火),解毒、消咽喉炎肿、镇痛、杀虫。现代药理,本品所含多种生物碱,有抗肿瘤作用。
木槿皮-调降肺、大肠内部偏高温度、稀释组织中的粘液度(逐饮)、抗菌、杀虫。古方用以治疗肺疽(肺肿瘤)有一定效果。现代药理说明,从木槿皮中分得7种单体化合物,其中的古柯三醇(erythrotriol)有抑制肿瘤细胞生长的作用。
天南星-祛除引发血管、微血管压力异常的病因(祛风),镇静、解痉、祛痰、淡化组织液稠粘度(逐饮)、通透淋巴组织。现代药理实验证实,本品对人肺、肝、胃、子宫等癌,有直接杀伤或抑制作用。
半边莲-平降组织内偏高温度,启动防御器官、促进解毒功能(清热解毒)。增进组织液代谢,消除腹水、足胫肿胀(利水消肿)。通透器官内部微淋巴代谢、中和有毒元素。现代药理说明,有利尿、利胆汁、抗蛇毒等作用,可治疗肝硬化腹水、多种癌症。
白蔹-调降组织内偏高温度,促进淋巴结及其它防御系统的解毒作用,缓解器官韧带及结缔组织的紧束状态;加速组织溃疡的愈合。现代药理实验,说明有抗菌作用。1992年李广勋氏所述白敛的体外试验,对人宫颈癌细胞培养系JTC-26有抑制作用,证明有抗癌效应。
漏芦-促进血液循环,以及产妇乳汁分泌;降低机体偏高温度,增进防御系统解毒功能。现代药理研究证明,有抗动脉粥样硬化、抗氧化、保肝、提高免疫功能等作用。
石苇-松弛摄护腺紧张,利尿;消除膀胱、尿道、摄护腺的发炎病象,治疗膀胱、尿道出血。现代药理研究,对下腹腔内的多种菌体、病毒有抑制作用。其杧果甙(mangiferin)有较强的抗单纯疱疹病毒的作用,能阻止病毒在细胞内复制。对于化学疗法、放射线疗法引起的白细胞下降,有使其升高的作用;可增强机体吞噬细胞能力。
乳香-促进血液、淋巴的正常循环,改善防御器官功能,配合他药,排除血栓、癌细胞及其它异物。
没药-促进血液循环,排除循环内异质的障碍;以疏通而达止痛效果。消除结缔组织的异常肿胀。现代药理研究证实,有调降血脂、胆固醇、防止动脉壁斑块形成的作用。可抑制肝匀浆胆固醇的形成。
四、通透淋巴结及其它必要作用:
蚤休-镇静神经,疏通淋巴器官及防御组织,排除其间异质。消除器官、组织、肝脏内的发炎、紧张病象。
败酱-调降偏高温度,增进防御系统解毒功能;排除血栓、脓液等体内异质。现代药理证实,有镇静、抗菌、抗病毒作用。高淑娟等氏在1992年天津中医里发表试验报告,谓可降低毒素活性,减毒倍数为8.7。
白芷-抗微生物、抗炎、解热。祛除导致微血管压力异常的病因(祛风);促进组织的水分代谢(利湿),消除鼻咽腔粘膜炎肿、镇痛,引导抗癌药物致达胸腔、头面部,使他药发挥治癌、改变癌环境的功能。
射干-抗炎、解热、稀释稠粘痰液,清利咽喉炎痛,消散淋巴结的结核。古籍记载,用本品可治疗肝、胰肿硬(疟母、伏梁)。现代药理,有抗炎、解热、祛痰、抗菌、抗流感病毒等作用。
蒲公英-促进淋巴组织内的通透性;排除机体内的有毒物质,偏高温度、发炎、肿胀。现代药理说明,有抗病原微生物、抗胃溃疡、利胆、保肝等作用。并有启动巨噬细胞、抗肿瘤的效能。
螺厣草-清除血液内激进成分,调降偏高体温,增进水分代谢功能,利尿,辅助防御,解毒、杀虫等功能。可通透胸肺部淋巴结,促进淋巴正常循环,加速治癌进度;故旧医药典籍记载,有消除下腹腔内肿块、沐巴结核、乳癌等作用。
皂荚-稀释组织液及体内稠粘物、祛痰、缓解气管、支气管内的痉挛、而有止咳作用;通利鼻腔、咽喉以及大小便的不畅。解除水分代谢障碍引发的毒素(祛湿毒),杀虫、灭菌。现代药理说明,有祛抗菌、溶血等作用。
独活-排除引发血管、微血管压力异常以及水分代谢障碍的病因(风湿因子),调整体温;镇痛、解痉。现代药理实验,有抗心律失常、延长血栓形成时间以及镇痛、解痉、抗炎、抗菌的作用。所含呋喃香豆精类成分,具有抑制P掺入HeLa细胞(人宫颈癌细胞)的作用;对艾氏腹水癌细胞有杀灭作用。
麻黄-兴奋中枢神经,增加神经、肌肉的传递功能,使治癌药物深入组织;是治疗肺、淋巴、骨癌必要的药物。
升麻-增进淋巴导管上升动能,增加淋巴细胞活性,诱导淋巴细胞产生干扰素,在小肠淋巴结(培氏斑)等处,以及胸腺以上淋巴结里产生特殊的作用,故虽非抗癌药物,却是治疗肠部、肺部、头颈部诸癌的重要药物。
药物说明资料表
表1
中草药名称 | 茯苓Fuling | 学名 | Poria cocos(schw.)WOLF. |
依据 | 中药大辞典第1596页,中华本草第1册第554页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 湖北、安徽产。栽种8~10个月成熟,扒开视察菌核表皮呈要褐色,即可收获,选晴天挖出,去泥砂,堆在室内盖稻草使发汗(水分),等苓皮起皱削去外皮,干燥。 | ||
炮制、萃取过程、方法 | (1)选体重、坚实,外皮棕褐、皮纹细、无裂隙、断面白色细腻、粘牙力强者,削去表皮,浸软、切薄片,干燥。(2)50kg粉碎,过120目筛为幼末收存。 | ||
有效成分 | 菌核含β-茯苓聚糖(β-Pachyman)约占干重93%,和三萜类化合物乙酰茯苓酸(Pachymicacid),3β-羟基羊毛甾三烯酸[3β-Hydroxylanosta-7.9(11),24-trien-21-oilacid]。此外,尚含树胶,甲壳质,脂肪,甾醇,卵磷脂,葡萄糖,腺嘌呤,组氨酸,胆碱,β茯苓聚糖分解酶,脂肪酶,蛋白酶等。另外还含有0.23%的无机元素(Ash),包括铁、钙、镁、钾、钠、铈、磷等。 | ||
原记载药理作用 | 补充营养,促进胰腺功能及免疫功能,安定神经系统,调整心律。增进机体水分代谢,利尿。现代药理,增强正常及荷瘤小鼠的免疫功能,提高巨噬细胞的吞噬能力:对鼻咽癌、胃癌、宫颈癌等多种癌症有正面效益。 | ||
药理应用、目的 | 补充营养,促进胰腺功能,免疫能力、水分代谢。在本发明中,主要用作赋形药,凡各种浓缩萃取药液,除部份以原药未收搅、干燥外,其余均用纯茯苓未收搅赋形,用以代替一般使用的玉米、小麦等食用淀粉。 |
表2
中草药名称 | 党参Dangshen | 学名 | Codonopsis Pilosula(Franch)Nannf |
依据 | 中药大辞典第1837页,中华本草第7册第607页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 山西、河南产。9~10月挖出根部洗净,晒4~6h,用小绳捆佳,揉搓使根充实,经反复3~4次处理,即可扎成小捆。 | ||
炮制、萃取过程、方法 | (1)4kg洗净,切段入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,至剩3公升膏液时,入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过80目筛为末,密封收贮。 | ||
有效成分 | 根中大部分含有果糖(fructose),菊糖(inulin)等多种糖类化合物;还含丁香甙(syringin)等四种甙类;另含胆碱(choline),黑麦草碱(perlolyrine)等生物碱及17种氨基酸。另含蒲公英赛醇(taraxerol)等12种甾醇及三萜成分;其它还有丁香醛(syringaldehyde)等酸、酯、醛类化合物以及铁、铜、钴、锰、锌、镍、锶、铝、钒、氟等无机元素。 | ||
原记载药理作用 | 增进胰腺、肺脏功能;补充营养,改善腺体素质与分泌。现代药理试验,证明有增强机体应激能力,免疫功能,有延缓衰老,抗溃疡等作用。对于血液、造血功能、心血管、抗肿瘤等均有正面效用。减轻肝脂肪变.改善肝坏死,抑制肝淋巴间隙及中央静脉下胶原纤维的形成。 | ||
药理应用、目的 | 增进胰腺功能,改善腺体分泌与素质;调和胰与各器官间的连系;补充柔和性营养、无机元素。 |
表3
中草药名称 | 黄芪Huanggi | 学名 | Astragalus mongholicusBge |
依据 | 中药大辞典第2036页,中华本草第4册第341页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 主产于山西、内蒙古,秋季深刨采挖根部,切去芦头,抖净泥土,晒半干,堆积2日,再日晒至全干,整形、扎成小捆。 | ||
炮制、萃取过程、方法 | (1)黄芪6kg,洗净,浸软切片,入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升浓液时,入1kg苓粉搅匀。(3)65℃干燥。(4)粉碎过100目筛为末,密封收贮。 | ||
有效成分 | 含黄芪甙(astragaloside)I、II、IV、大豆皂甙(soyasaponin)I,毛蕊异黄酮-7-O-β-D-葡萄糖甙(calycosin-7-O-β-D-glucoside)等多种甙、酮、酚、酯、多糖的成分,均具有增强免疫功能的作用。并含近二十多种微量元素,其中钙、磷、镁、铁等含量较高。 | ||
原记载药理作用 | 补充营养、微量元素、增强体力、增进淋巴导管上升动能;调节自律神经,防止汗腺异常过敏。利尿,调节机体水分代谢,改善淋巴体质,补充防御细胞养分。现代药理研究证实,对免疫系统有良性影响,对机体代谢、心血管系统有帮助;并有抗病毒、抗癌的作用。 | ||
药理应用、目的 | 调整胰腺功能,改善淋巴体质,补充防御细胞所需养分。增进淋巴导管上升动能;连系器官关系。 |
表4
中草药名称 | 薏苡仁yiyiren | 学名 | Coix Lacyma-Jobi L. |
依据 | 中药大辞典第2645页,中华本草第8册第329页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产。收取果实晒干,脱壳、筛去总苞和种皮。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,其1kg晒干研为细末,另5kg研为粗末,入锅水浸3h,加热以70℃为限,连续6h,分三次泄下流浸液。(2)加热挥发水分,至剩3公升时入薏苡仁细末搅匀。(3)65℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 含蛋白质16.2%,脂肪4.65%,碳水化合物79.17%,少量微生素B1,另含氨基酸薏苡素(coixul)、薏苡酯(coixenolide)、三萜化合物。 | ||
原记载药理作用 | 健全胰腺功能,改善器官,尤其是胰腺水分代谢障碍,清除肌肉,关节、韧膜内异常物质,消炎、排脓。现代药理实验,有抑制骨胳肌收缩、降血糖、解热、抗炎、扩张肺血管等作用。显著增加健康人末梢血单核细胞产生抗体,增强体力免疫与抗肿瘤的作用。 | ||
药理应用、目的 | 健全胰腺功能,改善器官水分代谢障碍,抗炎、排脓。 |
表5
中草药名称 | 山佩兰shanpeilan | 学名 | Eupatorium japonicumthunb. |
依据 | 中华本草第7册第838页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 台湾产。8、9月,割取地上部分,洗净,铺置通风风处使半干,再晒使全干。本植物与中药大辞典1377页记载的佩兰不同;可参阅中华本草第7册、838页。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,切段,其1kg晒干研末;另5kg入锅水浸3h,加热分二次煎取药液。(2)(2)加热挥发水分,剩3公升时入药末搅匀。(3)45℃干燥。(4)粉碎、过120目筛为幼末收贮。 | ||
有效成分 | 全草含己醛(hexanal),2-己烯醛(2-hexenal)龙脑(borneol),桃金娘醛(myrtenal),α-金合欢烯(α-farnesene)等38种挥发油。又含大牻牛儿烯(germacrene)D。叶含香豆精(coumarin),邻一香研酸(O-coumaric acid),麝香草氢醌(thymohydroquinone)。又从叶中分得白头婆内酯(eupanin),白头婆素(eupachifolin)A、B、C、D、E、华泽兰素(eupasimplicin)A、B及去乙酰基华泽兰素A(或B)[deacetyleupasimplicinA(or B)]。 | ||
原记载药理作用 | 增强人体抵抗天气暑热能力,发汗、解热;安定胰、胃、脾功能,促进局部组织水分代谢;促进血液循环,解除体内毒素。现代药理实验,具有抗宫颈鳞癌的作用。 | ||
药理应用、目的 | 安定胰、胃、脾的功能,促进血液、水分的循环,加强下腹腔内器官的通透性。 |
表6
中草药名称 | 橘皮(陈皮)chenpi | 学名 | Pericar,pium citrireticulatae |
依据 | 中药大辞典第2637页,中华本草第4册第886页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 为福建,江西产朱橘或福橘的果皮,先行风干、再晒干贮存于干燥、阴凉处。 | ||
炮制、萃取过程、方法 | (1)干陈皮4kg,淡盐水洗浸,切成条状,浸入健康人尿中24h;取出洗净,置于清洁流动水中漂浸24h以上,使去腥臭气味;以姜汁、纯米、醋、食盐水分别炒过,再干燥,并以1kg研末。(2)3kg入锅水浸3h,分二次煎取药液。(3)加热挥发水分,剩3公升浓液,入药末搅匀。(4)45℃干燥。(5)粉碎,过120目筛为幼末,密封收贮。 | ||
有效成分 | 原橘皮含挥发油1.2%-3.19%,主成分为柠檬烯(limonene),及其它烯、醛、醇等成分,又含黄酮类成分,橙皮甙,甲米橘素。还含β-谷甾醇,柠檬苦素,阿魏酸等,经尿,醋,姜,盐浸炒后药性变为缓和,并增强它在人体内的浸透性。 | ||
原记载药理作用 | 缓和上消化道神经过敏,矫味开胃、增进食欲,促进消化道器官水分代谢,祛除组织内稠粘物质。通导贲口、幽门神经;缓和气管、支气管过敏。 | ||
药理应用、目的 | 促进组织液、淋巴液、水分的新陈代谢,预防血液稠粘度的形成,调整胰、胃、肠的功能,改变癌环境。 |
表7
中草药名称 | 爵床Juechuang | 学名 | Rostellulariaprocumbens(L.)Nees. |
依据 | 中药大辞典第2682页,中华本草第7册第472页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产。8~9月盛花期采收,割取地上部分、晒干。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,切段,入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升浓液时,入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎、过120目筛为幼末收贮。 | ||
有效成分 | 含爵床脂定(justicidin)A,山荷叶素(diphyllin)爵床脂定(justicidin)E,新爵床脂素(neojusticin)A、B、C、D | ||
原记载药理作用 | 调降体内偏高温度,促进组织水分代谢,杀灭肝内细菌、微生物、排除肝内异质的障碍;帮助消化道蠕动,镇痛、消炎。现代临床研究、爵床有治疗虐疾、泌尿系感染、结核性肛瘘等效能。 | ||
药理应用、目的 | 消炎、解毒,促进水分代谢,调降门脉压。并用以处理直肠、大肠的偏高温度与淋巴循环。 |
表8
中草药名称 | 夏枯草xiakucao | 学名 | Prunella ulgaris L. |
依据 | 中药大辞典第1827页 | ||
产地、采收季节、部位 | 江苏、河南、安徽产。5~6月花穗变成棕褐色时,割起全草,捆成小把,晒干。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,切小段,入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升黑色浓液,入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎,过120目筛为幼末收贮。 | ||
有效成分 | 全草含三萜皂甙,其甙元是齐墩果酸(oleanolicacid),尚含游离的齐墩果酸,熊果酸(ursolic acid),芸香甙(rutin),金丝桃甙(hyperoside),顺一咖啡酸(caffelcacid),反一咖啡酸,维生素B1,维生素C,维生素K,胡萝卜素,树脂,苦味质,挥发油,生物碱,水溶性盐类(约3.5%,其中约68%是氯化钾)等。花穗含飞燕草素(delphinidin)和矢车菊素(cyanidin)的花色甙,d-樟脑(d-camphor)d-小茴香酮(d-fenchone),熊果酸。 | ||
原记载药理作用 | 改善眼睛周环血液循环,清除肝血窦障碍,通透肝循环,调降门脉压。通透淋巴腺,消除淋巴结的发炎、肿硬。现代药理,有显著的降血压作用,临床研究治疗黄疸型肝炎、肺结核有效。 | ||
药理应用、目的 | 清除肝循环障碍,改善淋巴,尤其是肝内微淋巴管的代谢,协同他药排除肝循环、肝血窦、门静脉管壁的有害异质。调降血压、门静脉压皆出于夏枯草通透、清除、解毒的药理。 |
表9
中草药名称 | 凉粉草liangfencao | 学名 | Me sona chinensis benth |
依据 | 中药大辞典第1915页,中华本草第7册第87页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产。夏季收割地上部分,晒至半干,推叠使的发酵、变黑,再晒至足干,收捆成束。 | ||
炮制、萃取过程、方法 | (1)6kg,洗,切,其1kg日晒研末,另5kg入锅水浸8h,加热分二次煎取药液。(2)加热挥发水分,剩3公升浓液,候冷入药末搅匀。(3)45℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 全草含凉粉草多糖(MCPS,mesona chinensis benthpolysaccharide),相对分子质量为43000,水解得葡卜糖(glucose),半乳糖(glactose),阿拉伯糖(arabinose),木糖(xylose),鼠李糖(rhamnose)和半乳糖醛酸(galacturonic acid),及一种未知糖。 | ||
原记载药理作用 | 能增加血液中阴柔元素,解除因天气暑热引起的人体不良影响,清除机体激进成分,而有解毒、解渴、清凉消炎的功效。可治疗高血压、糖尿病、民间用治性病感染的骨内疼痛。 | ||
药理应用、目的 | 解热毒,消炎,平降门脉压,改变癌环境的偏高温度,排除有害毒素。 |
表10
中草药名称 | 栀子zhizi | 学名 | Gardenia jasminoides ellis |
依据 | 中药大辞典第1984页,中华本草第6册第421页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产。10月中、下旬,果皮由绿色转为黄绿色时采收。除去果柄、杂物,置蒸笼中蒸熟,取出晒半干,再烘干,揉簸去果皮,留种仁用。 | ||
炮制、萃取过程、方法 | (1)6kg,慢火炒透,研为粗末,入锅浸于70℃温水中8h,分二次泄出药液。(2)挥发水分,剩3公升浓液时,入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过100目筛为细末收贮。 | ||
有效成分 | 含栀子甙(gardenoside),都桷子甙(geniposide),栀子酮甙(gardoside)等11种环烯醚甙类成分。又含绿原酸(chlorogenic acid),藏红花酸(crocetin)、藏红花素(crocin)等8种酸类成分。还含芸香甙(rutin)、胆碱(choline)等6种酮类成分。 | ||
原记载药理作用 | 清除血液中激进元素,调降偏高温,促进机体水分代谢功能;具有清凉、利胆、解热毒的作用。 | ||
药理应用、目的 | 促进机体水分代谢,清凉,利胆,解热毒,以平降门脉高压,疏通肝循环,消除癌的发炎环境。 |
表11
中草药名称 | 连翘Liangiao | 学名 | Forsythia suspensa(thunb)vahl |
依据 | 中药大辞典第1111页,中华本草第6册第155页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 山西、河南产。10月上旬,果实熟透变黄,果壳裂开时采收;晒干、筛去种子及杂质。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,分装入大型绢袋内,缚紧袋口,入锅,上压以重物,水浸8h,分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过100目筛为末收贮。 | ||
有效成分 | 含连翘甙(forsythin,phillyrin)等3种木脂体类化合物,芸香甙(rutin)以及连翘种甙(suspensaside)等3种苯乙烷类衍生物,还含连翘环己醇酮(rengyolone)等6种乙基环己醇类衍生物。另含白桦脂酸(betulinic acid),齐墩果酸(oleanolic acid),等6种三萜类化合物。 | ||
原记载药理作用 | 解热、消炎,解毒、利尿,通透淋巴,消除淋巴结的肿硬。现代药理实验,连翘有广效的抗微生物作用;有抗炎、抗肝损伤的效能;能强化末梢血管的强韧度,预防出血。 | ||
药理应用、目的 | 通透淋巴组织,改善变易的癌环境;特别用于解热、消炎、解毒,作为清凉降压药。 |
表12
中草药名称 | 赤芍chishao | 学名 | Paeonia Veitchii Lynch |
依据 | 中药大辞典第1093页,中华本草第3册第521页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川产。8-9月采挖,去除地上部分及泥土,晾晒至半干时,捆成小捆,再晒至全干。 | ||
炮制、萃取过程、方法 | (1)川赤芍5kg洗净、切片、入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过100目筛为末密封收贮。 | ||
有效成分 | 川赤芍根含芍药甙(Daeoniflorin),四川产品还含微量的苯甲芍药甙(benzoyl paconiflorin)。 | ||
原记载药理作用 | 促进血液循环,排除血栓,平降血液温度,解热。现代药理实验,有抗血栓形成,抗血小板聚集,降血脂和动脉硬化,抗肿瘤,保肝、改善血液循环的作用。 | ||
药理应用、目的 | 促进血液循环,通透下腹腔内器官的淋巴组织;协同他药,改善癌环境。 |
表13
中草药名称 | 大黄Dahuang | 学名 | Pheum pulmatum L. |
依据 | 中药大辞典第102页,中华本草第2册第708页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川产。取根及根茎,刮去外皮、整形、室内阴干四分,再以火烘干。 | ||
炮制、萃取过程、方法 | (1)大黄4kg,洗浸切片,1kg烘干研末,另3kg入锅水浸8h,加热分二次煎取药液。(2)加热挥发水分,剩3分升浓液,入药未搅匀。(3)65℃干燥。(4)粉碎过120目筛为幼末,收贮。 | ||
有效成分 | 含总蒽醌量2.034%-2.984%,其中游离蒽醌合量为0.037%-1.155%,结合蒽醌含量为1.829%-1.997%。还含掌叶大黄二蒽酮(palmldin)A、B、C等四种双蒽酮类成分。又含二苯乙烯甙类成分。苯丁酮类成分。又含树脂以及右旋儿茶精(catechin),左旋表儿茶精没食子酸脂(epicatechin gallate)、葡萄糖没食子鞣甙(glucogallin)等。 | ||
原记载药理作用 | 原记载与现代药理研究的结果颇相吻合,在消化系统中,有保肝、利胆、抗胃及十二指肠溃疡;阻止结肠内水分吸收、加快内容物排出而有导泻作用。有抗菌、抗病毒、抗真菌作用。以及抗炎、止血、降低血清总胆固醇等效能。 | ||
药理应用、目的 | 保肝、利胆、抗病毒,疏导,排除体内有害物质。 |
表14
中草药名称 | 虫Zhechong | 学名 | Eupolyphoqa sinensiswalker |
依据 | 中药大辞典第2684页,中华本草第9册第151页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 河南产。捕捉后,用沸水烫死,晒干。 | ||
炮制、萃取过程、方法 | (1)虫4kg,18度米酒浸洗,慢火炒干,使呈微黄色,1kg研成细末,另3kg入锅水浸3h,加热分二次煎取药液。(2)加热蒸发水分,使剩2升升浓液;入药未搅匀。(3)60℃干燥。(4)粉碎过120目筛为幼末收存。 | ||
有效成分 | 含多种脂肪酸(fatty acid),还含谷氨酸(glutamic acid)等17等氨基酸,又含具有血纤维蛋白溶酶原启动物样成分,并含生物碱以及胆甾醇(cholesterol)等醇类,另有钾、镁、钙、锌、磷等28种无机元素,尿密啶(uracil),尿囊素(allantoin)。 | ||
原记载药理作用 | 抗凝血,解除血管中血栓,对腱梢筋膜损伤及骨折复元有一定助益。现代药理:具有直接扩张血管作用,抗凝血、延缓动脉粥样硬化的形成 | ||
药理应用、目的 | 疏通小动脉、微血管的血液循环,缓解其间血栓。配合他药于微循环中带出败亡癌细胞或有害物质。 |
表15
中草药名称 | 白花蛇舌草Bai huashe-shecao | 学名 | Oldenlandia jiffusa(wild)roxb |
依据 | 中药大辞典第754页,中华本草第6册第433页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 产于安徽、广西及东南沿海各省。夏秋季采收全草,洗净、晒干,贮于阴凉干燥处。 | ||
炮制、萃取过程、方法 | (1)白花蛇舌草6kg,入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升黑色浓液,入1kg茯苓粉搅匀。(3)65℃干燥。(4)粉碎过120目筛为细末收贮。 | ||
有效成分 | 全草含车叶草甙(asperuloside),车叶草甙酸(asperulosidic acid),去乙酰基车叶草甙酸(deacetylasperulosidic acid),多种鸡屎藤次甙,甲脂蒽醌类等,以及熊果酸(ursolic acid)酸,β-谷甾醇(β-sitosterol),三十一烷,豆甾醇,齐墩果酸,对-香豆酸。 | ||
原记载药理作用 | 清除激进元素引发的偏高温度,解毒;促进局部组织、尤其是下腹腔内器官的水分代谢。现代药理试验,有增强白细胞吞噬能力,提高免疫功能,以及抗菌、抗肿瘤的作用。对于胃癌、直肠癌有一定的疗效。 | ||
药理应用、目的 | 清除激进元素,有毒物质;促进水分代谢与血液、淋巴循环。据应用经验,对于小肠集结淋巴球(培氏斑)、肠骨淋巴结的功能促进,有显著作用。 |
表16
中草药名称 | 扛板归Gangbangui | 学名 | Polygonum per foliatum L. |
依据 | 中药大辞典第869页,中华本草第2册第685页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产。夏秋季拨取全草及根茎,洗净,切段、晾干。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,入锅水浸8h,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 全草含山柰酚(kaempferol),咖啡酸甲酯(caffeic acidmethyl ester),懈皮素(quercetin),咖啡酸(caffeic acid),原儿茶酸(protocate chuic acid),懈皮素-3-β-D-葡萄糖醛酸甲酯(quercetin-3-β-D-glucuronide methylester),对香豆酸(P-coumaric acid),阿魏酸(ferulic acid),香草酸(Vanillicacid),熊果酸(ursolic acid),白桦脂酸(betulicacid),白桦脂醇(betulin),还含有甾醇脂肪酸脂,植物甾醇β-D-葡萄糖甙(Phytosteryl-β-D-glucoside),3,3′,4,4′-四甲基并没食子酸(3,3′,4,4′-tetramethylellagicacid),3,3′二甲基并没食子酸(3,3′-dimethylellgic acid),内消旋洒石酸二甲酯(dimethyl mesotartrate)及长链脂肪酸酯。另外还含有靛甙(indican)和鞣质。根及根茎另含少量大黄素(e-modin)和大黄酚(chrysophand)。 | ||
原记载药理作用 | 促进机体水分代谢,利尿,消肿,解热;排除组织内血栓、毒素,民间用以治疗淋病感染及性病疾患,以及腹水症。现代药理实验,有抗菌、抗病毒、抗肿瘤等作用。 | ||
药理应用、目的 | 协同他药增强抗菌、抗病毒、抗肿瘤效能,并禀其促进水分代谢药理,迅速把有害素质排出体外。 |
表17
中草药名称 | 山豆根Shandougen | 学名 | Sophora tonkinensisGagnep |
依据 | 中药大辞典第181页,中华本草第4册第652页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 广西产,秋季采收根部,除去杂质,洗净,晒干。 | ||
炮制、萃取过程、方法 | (1)5KG洗净,浸切,1KG烘干研末,另4KG入锅水浸8H,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入原药末搅匀。(3)65℃干燥。(4)粉碎过120目筛为细末收贮。 | ||
有效成分 | 含苦参碱(matrine),氧化苦参碱(oxymatrine),臭豆碱(Anagyrine)和甲基金雀花碱(methylcytisine)等生物碱。各类黄酮成分,柔枝槐酮(sophoranone)柔枝槐素(sophoradin),柔枝槐酮色烯(sophoranochromene),柔枝槐素色烯(sophoradochromene),染色木素(genistein),紫檀素(pterocarpine),山槐素(maackian),红车轴草根甙(trifolirhizin),谷甾醇,蛇麻脂醇,一群咖啡酸的高级烷醇酯以及一种未定的青色萤光物 | ||
原记载药理作用 | 清除体内激进元素(退火),中和有毒元素(解毒);消咽喉发炎、肿胀,镇痛、杀虫。现代药理,本品含有的多种生物碱有抗肿瘤作用。 | ||
药理应用、目的 | 清除体内激进元素,中和有毒元素,减轻防御系统的负担。 |
表18
中草药名称 | 木槿皮Mujinpi | 学名 | Hibiscus syriacus L. |
依据 | 中药大辞典第366页,中华本草第5册第357页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 台湾产。4、5月,割取地上部分,削去花、叶、幼枝,留尾指大小以上茎,重器捶破硬骨,取皮,切段晒干。 | ||
炮制、萃取过程、方法 | (1)5kg洗净,入锅水浸8h,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)45℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 含辛二酸(suberic acid),l-二十八醇(1-octacosand),β-谷甾醇(β-sitosterol),1,22-二十二碳二醇(1,22docosanediol),白桦脂醇(betulin),古柯三醇(erythrotriol),壬二酸(nonanedioic acid);又含脂肪酸包括肉豆蔻酸(myristic acid),棕榈酸(palmitic acid),月桂酸(lauric acid),另含铁屎米酮(canthin-6-one)。 | ||
原记载药理作用 | 调降肺、大肠部偏高温度,稀释组织中的稠粘度(逐饮),抗菌、杀虫。右方用以治疗肺疽(肺肿瘤)有效。现代药理说明,从木槿皮中分得7种单体化合物,其中的古柯三醇(erythrotriol)有抑制肿瘤细胞生长的作用。 | ||
药理应用、目的 | 调降肺、大肠组织内偏高温度,稀释淋巴组织中的稠粘度,以改善防御功能。信任古籍治疗肺肿瘤经验以及现代药理说明,直接作用于肺、肠等部癌细胞,配合他药,改善体内环境。 |
表19
中草药名称 | 天南星Tiannanxing | 学名 | ArisaemaHeterophyllum B1 |
依据 | 中药大辞典第329页,中华本草第8册第504页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 江西产。10月挖出块茎,去掉泥土及茎、叶、须根,装入撞兜(木桶型制药用具)内撞搓,撞去表皮,倒出洗净,再用竹刀刮净表皮,最后用硫黄熏制,使其色白,晒干。 | ||
炮制、萃取过程、方法 | (1)取粒体大小接近天南星3KG,水漂浸,每日换水2~3次,候起白沫时再换水,并加入白矾120mg,泡浸1日后再换水,至切开口尝微有麻舌感时取出。(2)取泡过天南星加生姜片1KG煮4H,取出晾至8成干,切片,晒干。(3)取1KG研末,另2KG入锅水浸3H,加热分二次煎取药液。(4)挥发水分,剩2.5KG时入原药末搅匀。(5)65℃干燥。(6)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 含L-脯氨酰-L-缬氨酸酐(L-prolyl-L-valine anhydride),脲嘧啶(uracil),胸腺嘧啶(thymine),烟酰胺(nicotinamide)等多生物碱和环二肽类化合物成分以及掌叶半夏碱(pedatisectine)A、B、C、D、E。还含胡萝卜甙(daucosterol),β-谷甾醇(β-stitosterol),棕榈酸(palmitic acid)以及脯氨酸(proline)等30多种氨基酸和20多种无机微量元素。 | ||
原记载药理作用 | 祛除引发血管、微血管压力异常的病因,镇静、解痉;祛痰、淡化组织液稠粘度,通透淋巴组织。现代药理实验,本品对人肺、肝、胃、子宫等癌,有直接杀伤或抑制作用。 | ||
药理应用、目的 | 调整微血管的正常压力,淡化组织液稠粘度,通透淋巴组织,协同他药,改善变易的癌环境。 |
表20
中草药名称 | 半边莲Banbianlian | 学名 | Lobelia chinensis lour |
依据 | 中药大辞典第754页,中华本草第7册第613页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 安徽,福建,台湾产。夏、秋季割取全草,洗净,晾晒使干。 | ||
炮制、萃取过程、方法 | (1)半边莲4KG,入锅水浸3H,分二次煎取药液。(2)加热挥发水分,使剩3公升浓汁,入茯苓粉1KG搅匀。(3)60℃干燥。(4)粉碎过120目筛幼末,防湿包装收存。 | ||
有效成分 | 全草含生物硷,主要为L-山梗菜盐(L-lobeline),山梗菜酮盐(lobelanine),山梗菜醇盐(lobelanidlne),异山梗菜酮盐(isolobelanine),即去甲山梗菜酮盐,黄酮甙,皂甙,氨基酸,多糖,菊糖(inulin),对一羟基苯甲酸(p-hy-droxyacid)和琥珀酸(succinicacid)。根茎含半边莲果聚糖(lobelinin)。 | ||
原记载药理作用 | 平降组织内偏高温度,启动防御器官,促进解毒功能(清热解毒)。增进水分代谢,消除腹水,足胫肿胀(利水消肿)。通透器官内部微淋巴代谢,中和毒素。现代药理:有利尿、利胆汁、抗蛇毒等作用,可治疗肝硬化腹水、多种癌症。 | ||
药理应用、目的 | 通透器官深部微淋巴循环;启动防御器官,促进解毒功能。1976年发明人曾于台湾南部七县市、中医学术研讨会中发表半边莲的考证与应用一文;说明其在治疗方剂中的功效;可惜因为某种因素,而不被认同;且由后续的研究者撰文述其毒性,且被收录于台湾有毒植物志书中。 |
表21
中草药名称 | 白蔹bailian | 学名 | Ampelopsis joponica(thunb)makino |
依据 | 中药大辞典第691页,中华本草第5册第276页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 安徽、江西产。春、秋季采挖,除去茎及须根,洗净,纵切成两瓣,晒干。 | ||
炮制、萃取过程、方法 | (1)6KG洗净,1KG研为细末,另5KG研为粗粒,入锅水浸,加热以70℃为限,经3H。分3次泄下浸液。(2)加热挥发水分,剩3公升浓液,入原药末1KG搅匀。(3)65℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 含粘质和淀粉洒石酸(tartaric acid),β-谷甾醇(β-sitosterol),延胡索酸(fumaric acid),胡萝卜甙(daucosterol)。 | ||
原记载药理作用 | 调降组织内的异常高温,促进淋巴结及其它防御系统的解毒作用,解除器官韧带及结缔组的紧束状态,加速组织溃疡的愈合。现代药理实验,说明有抗菌作用。1992年李广勋氏所述白蔹的体外试验,对人宫颈癌细胞培养系JTC-26有抑制作用,证明有抗癌效应。 | ||
药理应用、目的 | 深入淋巴、防御组织,以舒缓、解毒的作用,配合他种药物,改变癌环境。 |
表22
中草药名称 | 漏芦loulu | 学名 | Echinops latifolius tausch |
依据 | 中药大辞典第2576页,中华本草第7册第976页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 山东,河南,台湾(阿里山)产。秋后采收,除去泥土,叶茎残基,取地下根茎晒干。 | ||
炮制、萃取过程、方法 | (1)6KG浸干、切片,1KG晒,研为末,另5KG入锅水浸3H,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入原药末1KG搅匀。(3)45℃干燥。(4)粉碎过100目筛为末收贮。 | ||
有效成分 | 根含柠檬烯(limonene)、薄荷酮(menthone)等24种挥发油成分。又含地榆糖甙(ziyugluooside),1,蒲公英赛醇乙酸酯(taraxerol acetate),熊果酸(ursonicacid),三十烷酸(triacontanoic acid),β-谷甾醇(β-sitosterol),胡萝卜甙(daucosterol)。 | ||
原记载药理作用 | 促进血液循环,以及产妇乳汁分泌,降低机体偏高温度,增进防御系统解毒功能。现代药理研究证实,有抗动脉粥样硬化、抗氧化、保肝、提高免疫功能等作用。 | ||
药理应用、目的 | 经发明人研究,实验发觉,多数促进产妇乳汁分泌的药物,同时有促进淋巴循环的效能。本药物即为其中的例,观其主治,疮疖肿毒、乳腺炎、淋巴结核、痔瘘等症,均与淋巴结有关。通透培氏斑、肠骨淋巴结、鼠蹊淋巴结,以达促进肾脏、下腹腔内淋巴通透是主要的药理目的。 |
表23
中草药名称 | 石苇Shiwei | 学名 | Pyrrosia sheareri(Bak)ching |
依据 | 中药大辞典第579页,中华本草第2册第253页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 庐山石苇、台湾、福建产。全年均采收,洗净、晒半干、再阴干。 | ||
炮制、萃取过程、方法 | (1)石苇8KG,入锅水浸8H,加热分二次煎取药液。(2)加热挥发水分,3公升时入茯苓粉1KG搅匀。(3)65℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 全草含里白烯(diploptene),杧果甙(mangiferin),香草酸(vanillic acid),原儿茶酸(protocatechuic acid),延胡索酸(Furnaric acid),咖啡酸(caffeic acid),β谷甾醇(β-sitosterol),蔗糖(sucrose),异杧果甙(isomangiferin),绿原酸(chlorogenic acid) | ||
原记载药理作用 | 松弛摄护腺紧张,利尿;消退膀胱、尿道、摄护腺的发炎病象,治疗膀胱、尿道出血。现代药理研究,对下腹腔内的多种菌体、病毒有抑制作用。其杧果甙(mangiferin)有较强的抗单纯疱疹病毒的作用,能阻止病毒在细胞内复制。对于化学疗法、放射线疗法引起的白细胞下降,有使其升高的作用;可增强机体吞噬细胞能力。 | ||
药理应用、目的 | 改善下腹部脏器发炎、紧束病象,协同他药,增强防御功能。 |
表24
中草药名称 | 乳香ruxiang | 学名 | Boswellig carterii birdw |
依据 | 中药大辞典第1379页,中华本草第5册第1 7页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 主产于希腊、土耳其等国的进口中药,是切伤乳香树皮后,流出的油胶树脂。 | ||
炮制、萃取过程、方法 | (1)乳香,以灯心草,煅制过者4KG,入锅水浸3H,加热分二次煎取药液。(2)加热挥发水分,剩3公升乳糜色浓液,入1KG茯苓粉搅匀。(3)50℃干燥。(4)粉碎过100目筛为末,密封收贮。 | ||
有效成分 | 乳香树含树脂60%-70%,主要成分为游离α,β-乳香脂酸(α,β-boswellicacid)33%,乳香树脂烃(olibanoresene)33%,含树脂27%-35%,树胶为阿拉伯杂多糖酸(arabicacid)的钙盐和镁盐20%,含挥发油3%-8%,呈淡黄色,有芳香,含多种烯、醛、酮的成分。 | ||
原记载药理作用 | 促进血液、淋巴液的循环,消除组织间淋巴、血栓的异常聚集;镇痛,消肿。 | ||
药理应用、目的 | 促进血液、淋巴的正常循环,改善防御器官功能,配合他药,排除血栓,癌细胞及其它异常物质。 |
表25
中草药名称 | 没药Moyao | 学名 | Commiphora Myrrha Engl |
依据 | 中药大辞典第1167页,中华本草第5册第26页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 产于索马尼亚国,橄榄科植物,没药树的树干皮部渗出的油胶树脂;自古即是进口中药。 | ||
炮制、萃取过程、方法 | (1)没药、以灯心草(juncus effusus L.Var)煅制过者4kg,入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升浓液,入1kg茯苓粉搅匀。(3)50℃干燥。(4)候冷,粉碎过100目筛,密封收贮。 | ||
有效成分 | 含树脂25%-35%,挥发油2.5%-9%,树胶约57%-65%,树胶水解得阿拉伯糖,半乳糖和木糖。挥发油在空气中易树脂化,含酚,醛,烯成分,并含多种呋喃倍半萜类化合物。 | ||
原记载药理作用 | 促进血液循环,排除循环内异质的障碍;以疏通而达止痛效果。消除结缔组织的异常肿胀。现代药理研究证实,有调降血脂,胆固醇,防止动脉壁斑块形成的作用。可抑制肝匀浆胆固醇的形成。 | ||
药理应用、目的 | 促进血液的正常循环,协同他药,排除毒素、细菌、癌因子等有害物质。 |
表26
中草药名称 | 蚤休zao xiu | 学名 | P.chinensis Franch |
依据 | 中药大辞典第1748页,中华本草第8册第130页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建,台湾产,在9-10月秋季曲叶枯倒时,挖起根茎,晒干或烘干后,撞去粗皮,须根。 | ||
炮制、萃取过程、方法 | (1)华重楼品种的蚤休4KG,洗净,切片,1KG烘干研末,另3KG入锅加水浸3H,加热分二次煎取药液。(2)加热挥发水分,剩3公升入药末搅匀。(3)65℃干燥。(4)粉碎过120目筛为幼末收贮。 | ||
有效成分 | 根茎含薯蓣皂甙元-3-O-α-L-呋喃阿拉伯糖基(1→4)-[α-L-呲喃鼠李糖基(1→2)]-β-D-呲喃葡萄糖甙{diosgenin-3-o-α-L-arabinofuranosyl(1→4)-[α-L-rhamnopyranosyl(1→2)]}-β-D-glucopyranoside},以及多种皂甙元,糖基,糖甙等成分。 | ||
原记载药理作用 | 镇静神经,疏通淋巴器官及防御组织,排除其间异质,消除器官,组织,肝脏内的发炎现象。 | ||
药理应用、目的 | 疏通淋巴器官及防御组织,排除其间异质。 |
表27
中草药名称 | 败酱Baijiang | 学名 | Patrinia Villosa(thunb.)juss |
依据 | 中药大辞典第1340页,中华本草第7册第570页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川、福建产。夏季采收,拔起全草,洗净、晒干。 | ||
炮制、萃取过程、方法 | (1)8kg洗净、切段,入锅水浸8H,加热分二次煎取药液。(2)加热挥发水分,剩3公升浓液时,入茯苓粉1kg搅匀。(3)45℃干燥。(4)粉碎、过120目筛为幼末收贮。 | ||
有效成分 | 白花败酱含白花败酱甙(villoside),马钱子甙(loganin),莫罗忍冬甙(morroniside),白花败酱醇(villosol),白花败酱醇甙(villosolside),齐墩果酸,棕榈酸(palmiticacid),还含肌醇(inositol)。 | ||
原记载药理作用 | 调降偏高体温,增进防御系统解毒功能;排除血栓、脓液,现代药理有镇静、抗菌、抗病毒作用。高淑娟等氏在1992年天津中医里发表试验报告,谓100%败酱液加入10mg内毒素,可降低毒素活性,减毒倍数为8.7, | ||
药理应用、目的 | 败酱的药理作用,在下腹部器官中最为显著,用以为清凉退热,排脓解毒,使局部环境趋向正常。 |
表28
中草药名称 | 白芷Baizh | 学名 | Angelica dehurica |
依据 | 中药大辞典第675页,中华本草第5册第883页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川、浙江产,8-10月下旬,候叶枯萎时采收,抖去泥土,烘干。 | ||
炮制、萃取过程、方法 | (1)6KG洗净,切片,1KG研为细末,另5KG入锅水浸,加温以70℃为限,经8H,分三次泄下药液。(2)加热挥发水分,剩3公升黄色浓液时入原药末1KG搅匀。(3)45℃干燥。(4)粉碎,过120目筛为幼末收贮。 | ||
有效成分 | 含欧前胡内酯(imperatorin)等四种前胡内酯,氧化前胡素(oxypeucedanin),等三种前胡素,白当归素(byakangelicin),白当归脑(brakangclicol),新白当归脑(neobyakangclicol),珊瑚菜素(phellopterln),花椒毒酚(xanthotoxol),香柑内脂(bergapten),补骨脂素(cnidilin),栓翅芹烯醇(pabulenol)等多种香豆精类成分。还含有谷甾醇(sitosterol),棕榈酸(palmitic acid)及钠、镁、钙、铁、磷等11种元素。 | ||
原记载药理作用 | 抗微生物,治感冒风寒,抗炎、解热。祛除导致微血管压力异常的病因(祛风);促进局部组织的水分代谢(利湿),消除鼻咽腔粘膜炎肿,镇痛。 | ||
药理应用、目的 | 引导其它药物到达头部,胸部,使发挥抗癌,治癌的效能。祛除微血管压力异常的病因,改善组织水分代谢作用,抵御外在环境的侵袭。 |
表29
中草药名称 | 射干shegan | 学名 | Belamcanda chinensis(L.)DC |
依据 | 中药大辞典第1883页,中华本草第8册第256页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产,春、秋季挖掘根茎,洗净晒半干搓去须根,再晒至全干 | ||
炮制、萃取过程、方法 | (1)5kg洗净,入浆水(米饭汤隔24h后的汤液)浸24h,取出漂洗,切片;入锅水浸、加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过120目筛为细末收贮。 | ||
有效成分 | 含射干定(belamcandin),鸢尾甙(lridin)鸢尾黄酮甙(tectoridin),鸢尾黄酮(tectorigenin)。 | ||
原记载药理作用 | 抗炎、解热,祛痰,清利咽喉炎痛,通透淋巴,消散淋巴结核。古籍记载,用本品治疗肝、胰肿硬(疟母,征痞)有效.现代药理,有抗炎,解热,祛痰,抗微生物(炭疽杆菌,白喉杆菌,伤寒杆菌,人型结核杆菌),以及流感病毒等作用。 | ||
药理应用、目的 | 通透淋巴,抗炎,解热,祛痰,抗杀侵袭机体的部分微生物,改善恶劣环境,间接增进防御功能及进度。 |
表30
中草药名称 | 蒲公英Pugongying | 学名 | Taraxacum mongolicumHand Mazz |
依据 | 中药大辞典第2459页,中华本草第7册第986页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 福建、台湾产。4~5月开花前或刚开花时连根挖取,洗净、晒干。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,入锅水浸3h,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过120目筛为细末收贮。 | ||
有效成分 | 全草含蒲公英甾醇(taraxasterol),胆碱(choline),菊糖(inulin),果胶(pectin)等。 | ||
原记载药理作用 | 促进淋巴组织的通透性,排除机体内的有毒物质。偏高温度、发炎、肿胀、现代药理说明,有抗病原微生物、抗胃溃疡、利胆、保肝等作用,并有启动巨噬细胞,抗肿瘤的药效。 | ||
药理应用、目的 | 自古即用为淋巴结肿硬的有效药,在促进淋巴组织的通透性,协同他药,解除淋巴内毒素,偏高温度、炎肿方面,已有一定的作用。 |
表31
中草药名称 | 螺厣草luoyancao | 学名 | Lemmaph yllummicrophyllum presl |
依据 | 中药大辞典第1322页,中华本草第2册第228页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 台湾产,中药大辞典名抱树莲。全年均可采收,洗净、晒干。 | ||
炮制、萃取过程、方法 | (1)6kg洗净,入锅水浸8h,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1kg搅匀。(3)65℃干燥。(4)粉碎过120目筛为细末收贮。 | ||
有效成分 | α-芒柄花二烯(α-onoceradiene)等七种三萜化合物;还含有蕨甾醇(pterosterone)等三种甾体化合物。 | ||
原记载药理作用 | 清除血液内激进成分,调降偏高体温,增进水分代谢功能,利尿,辅助防御、解毒、杀虫等功能。旧医药典籍记载,有消除下腹腔内肿块,淋巴结核,乳癌等作用。经验上对于痔疮、肠炎、便闭以及泌尿系统疾患的疗效颇显著。 | ||
药理应用、目的 | 清除下腹腔内器官的发炎病象;并可通透胸、肺部淋巴结,促进淋巴正常循环,加速治癌进度。 |
表32
中草药名称 | 皂荚zaojia | 学名 | Cleditsia sinensis lam |
依据 | 中药大辞典第1144页,中华本草第4册第480页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川产。秋季果实成变黑时采摘,只选略扁,弯曲作镰刀状者(猪牙皂),晒干。 | ||
炮制、萃取过程、方法 | (1)4KG修剪去其弦边,蜜水炒透,1KG晒干研末,另3KG入锅水浸3H,加热分二次煎取药液。(2)加热挥发水分,剩2.5公升浓液时入原药末搅匀。(3)45℃干燥。(4)粉碎过100目筛为细末,密封收贮。注:粉末有刺激鼻粘膜的催嚏性,工作人员需带口罩。 | ||
有效成分 | 含皂荚甙(gledinin)其甙元为皂荚甙元(gledigenin),皂荚皂甙(gleditschia saponin),尚含蜡醇(ceryl alcohol),二十九烷(nonacosane),正二十七烷(heptacosane),豆甾醇(stigmasterol),谷甾醇(sitosterol),鞣质(tannin)等。 | ||
原记载药理作用 | 稀释组织液及体内稠粘物,祛痰,缓解气管,支气管的痉挛,而有止咳作用;通利鼻腔、咽喉,以及大小便,解除水分代谢障碍引证的毒素(湿毒),杀虫,灭菌。现代药理说明,有祛痰、抗菌、溶血等作用。 | ||
药理应用、目的 | 化痰,稀释或排除稠粘物(逐饮)的中医药很多,各有它适治的层次、部位;并有它适宜的配伍。本品主要用以稀释、排除淋巴结与肺泡附近的粘稠物;古方配合半边莲、麻黄,对于顽固性肺疾患、肺腺癌,皆能取得一定的效益。 |
表33
中草药名称 | 独活Duhuo | 学名 | Angelica biserrate |
依据 | 中药大辞典第1703页,中华本草第5册第877页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川产。10-11月,挖出根,去除枯萎茎叶,抖去泥土,摊晾干部分水气后,推放炕楼上,用柴火熏炕,炕至五成干时,将每枝顺直捏拢,扎成小捆,再炕至全干。 | ||
炮制、萃取过程、方法 | (1)4KG洗净,切开,入锅水浸3H,加热分二次煎取药液。(2)加热挥发水分,剩3公升浓液时入茯苓粉1KG搅匀。(3)65℃干燥。(4)粉碎过100目筛为末,密封收贮。 | ||
有效成分原记载药理作用药理应用、 | 含当归醇(angelol),当归素(angelicone glabralactone),佛手柑内酯(bergapten),欧芹酚甲醚(osthol),伞形花内脂(umbelliferone),东茛菪素(scopoletin),当归酸(angelicacid),巴豆酸(tiglic acid),棕榈酸(palmitic acid),硬脂酸,油酸,亚麻酸,植物甾醇,葡萄糖和少量挥发油。排除引发血管、微血管压力异常以及水分代谢障碍的病因(风湿因子)、调升偏低体温;镇痛、解痉。现代药理实验,有抗心律失常,延长血栓形成时间,以及镇痛,解痉,抗炎、抗菌的作用。所含呋喃香豆精类成分,具有抑制P掺入HeLa细胞(人宫颈癌细胞)的作用,对艾氏腹水癌细胞有杀灭作用。调整微血管压力,组织内水分代谢,以及偏低温,经 | ||
目的 | 验上及旧籍记载,独活有深入组织,改善异常病况的作用。中草药名称 | ||
表34
中草药名称 | 麻黄Mahuang | 学名 | Ephedra sinica stapf |
依据 | 中药大辞典第2221页,中华本草第2册第349页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 主产于山西、内蒙古。秋季割取绿色茎枝,挂通风处使有六成干,再晒干,捆住收藏。 | ||
炮制、萃取过程、方法 | (1)草麻黄4KG洗净,切寸断,入锅水浸3H,加热去上面白色浮沫,分二次煎取药液。(2)慢火挥发水分,剩3公升浓液,入1KG茯苓粉搅匀。(3)45℃干燥。(4)粉碎过120目筛为细末收贮。 | ||
有效成分 | 含左旋麻黄碱(ephedrine),右旋伪麻黄碱(pseudoephedrine),等6种麻黄生碱类;恶唑酮类生物碱;以及分离出32种化合物的挥发油;并黄酮类化合物。 | ||
原记载药理作用 | 发汗解热,抗炎,利尿,对呼吸系统有平喘,镇咳,祛痰的作用。兴奋中枢神经,增加神经,肌肉的传递功能。 | ||
药理应用、目的 | 兴奋中枢神经,增加神经,肌肉的传递功能,俾使治癌药物深入组织,是治疗肺癌及淋巴癌、骨癌必要的药物。 |
表35
中草药名称 | 升麻Sheng ma | 学名 | Cimicifuga foetida L |
依据 | 中药大辞典第451页,中华本草第3册第175页(中国上海科学技术出版社) | ||
产地、采收季节、部位 | 四川产,秋季地上部份枯萎后,挖出根茎,去净泥土,晒至八成干,用火烧去须根,再晒至全干,撞去表皮及残存须根。 | ||
炮制、萃取过程、方法 | (1)6KG浸润,切片,入锅水浸3H,加热分二次煎取药液。(2)加热挥发水分,剩3公升时入茯苓粉1KG搅匀。(3)65℃干燥。(4)粉碎过120目筛为细末贮存。 | ||
有效成分 | 含升麻碱(cimicifugine),水杨酸,鞣质,树脂,咖啡酸(caffeicacid),阿魏酸(ferulic acid)等及其它不明成分。 | ||
原记载药理作用 | 解热,抗炎,解毒;促进淋巴导管的淋巴液上升,提高肺部呼吸量。疏通末梢血管,使麻疹病毒透发于表皮。现代药理说明,升麻有解热,降温,抗炎,抗惊厥,护肝,解痉的作用,升麻三萜类化合物,能增进淋巴细胞的活性;升麻提出物能诱导淋巴细胞产生干扰素。 | ||
药理应用、目的 | 增进淋巴导管上升动能,增进淋巴细胞活性,透导淋巴细胞产生干扰素,在小肠淋巴结(培氏斑)以及胸腺以上淋巴结里产生特殊的作用,故虽非抗癌药物,却是治疗、肠部癌、肺癌及头部诸癌的主导性药物。 |
为实现本发明目的,以上述理论为依据,本发明提供的一种治疗淋巴结关系型癌症的中药,包含有:
(a)增进胰腺功能及与各器官联系的药物:
其药物为下述的药物:党参、黄芪、薏苡仁、山佩兰、橘皮;
(b)排除门静脉、肝、脾内的通透、障碍,平降门脉压的药物:
其药物为下述的药物:爵床、夏枯草、凉粉草、栀子、连翘、赤芍、大黄、虫;
(c)改善防御功能、淋巴循环、提高免疫力的药物:
其药物为下述的药物:白花蛇舌草、扛板归、山豆根、木槿皮、天南星、半边莲、白蔹、漏芦、石苇、乳香、没药;
(d)通透淋巴结及其它必要作用的药物:
其药物为下述的药物:蚤休、败酱、白芷、射干、蒲公英、螺厣草、皂荚、独活、麻黄、升麻;
上述药物可依癌患病理的微异而舍取药物及酌以增减。
具体的讲,本发明提供的一种治疗淋巴结关系型癌症的中药,包含有党参、黄芪、薏苡仁、山佩兰、橘皮、爵床、夏枯草、凉粉草、栀子、连翘、赤芍、大黄、虫、白花蛇舌草、扛板归、山豆根、木槿皮、天南星、半边莲、白蔹、漏芦、石苇、乳香、没药、蚤休、败酱、白芷、射干、蒲公英、螺厣草、皂荚、独活、麻黄、升麻药物。
所述的一种治疗淋巴结关系型癌症的中药,其特征在于它是由下述重量配比的原料制成的:党参1.94%-3.94%、黄芪1.94%-3.94%、薏苡仁1.94%-3.94%、山佩兰1.94%-3.94%、橘皮1.94%-3.94%、爵床1.94%-3.94%、夏枯草1.94%-3.94%、凉粉草1.94%-3.94%、栀子1.94%-3.94%、连翘1.94%-3.94%、赤芍1.94%-3.94%、大黄1.94%-3.94%、虫1.94%-3.94%、白花蛇舌草1.94%-3.94%、扛板归1.94%-3.94%、山豆根1.94%-3.94%、木槿皮1.94%-3.94%、天南星1.94%-3.94%、半边莲1.94%-3.94%、白蔹1.94%-3.94%、漏芦1.94%-3.94%、石苇1.94%-3.94%、乳香1.94%-3.94%、没药1.94%-3.94%、蚤休1.94%-3.94%、败酱1.94%-3.94%、白芷1.94%-3.94%、射干1.94%-3.94%、蒲公英1.94%-3.94%、螺厣草1.94%-3.94%、皂荚1.94%-3.94%、独活1.94%-3.94%、麻黄1.94%-3.94%、升麻1.94%-3.94%。
所述的治疗淋巴结关系型癌症的中药,上述各原料重量配比为均等。
所述的治疗淋巴结关系型癌症的中药,是利用茯苓作为赋形剂。
具体实施方式
药物制备
将上列经浓缩萃取(方法参阅各药物说明资料)药粉,按所列百分比配合,经混合机充分混合后,加入适当水分搅微湿,再以打锭机制成每颗0.5gm的锭片,45℃干燥去水分,装入玻璃瓶中密封贮存,置于干燥、阴凉处备用。
使用方法
凡进行肝癌、胰腺癌、食道癌、贲口、幽门、胃癌的外的广泛性癌种别,经诊断确定,不论原发、转移、期别,是否经过割、栓、化、放的治疗,只要属于此广泛性、进行性的癌症,均可使用。每饭后90min,以白开水吞服(咬碎亦可)8颗(4gm),日服三次,小儿酌减或减半。
注意事项
经割、栓、化、放疗者,须隔10天以上服用,服药期间勿再、栓、化、放疗,勿兼服其它药物或健康食品,以免妨碍药效。禁食葱蒜韭
酒、花椒、鲁料、五香料等躁热食品。住处不可燃烧蚊香、喷洒灭蚊、杀虫剂等有毒气质;勿作剧烈运动、暂停交际、应酬。
临床试验
1.试验目的、说明:
在一定规范内,持续给予一种治疗广泛性癌症的中药复方内服,以测试其实际疗效,并归纳统计。
为顾及参与者宝贵生命、试验的持续,在过程中、若遇非癌疾病、偶发症候时,皆临时另用药物处治,但本试验内服药仍然持续,并不直接影响试验效果。
编列本案临床试验实施例的资料、档案,部分保存于本试验单位,诊断确据则在各相关医院的病历诊断数据库,依台湾有关法规、再一定时间内有必须保存的规定。
2.实施例的一定规范:
入案排除:未经设备齐全的三级以内大医院的科学诊段确定的,予以排除。属于肝癌、胰腺癌、食道癌、胃及贲口癌者排除。试验日期不足3疗程(每疗程12天)的,恐有疗效评定误差而排除。
起讫年月:已受试日为准,自1997年3月2日起,至2002年10月2日终止;凡合乎上述规范者,不论癌种型、期级别、疗效结果,一律纳入
实施例,并予以统计。
3.疗效评定的标准:
依据1972年关于中药治癌症疗效标准通知;分显效、有效、无效三种。
显效:症状基本消失,癌病灶缩小一半以上,其它客观检查有明显好转。I级规定半年以上不再复发;II级规定2-6各月不再发展。
有效:症状有所改善,病灶基本稳定,规定一个月以上。
无效:症状及客观检查无改善,或短期改善、又有迅速恶化。
备注:除上列有关规定的外,再本实施例中,凡受试者响应不明确,或失联而难以评定者,另定为不详。受试者症状有所改善,病灶基本稳定虽超过一个月,但若在本试验进行中,突生变化、或回复原症状,均归类于无效。
效率、统计
符合本试验规范的癌患共计83人。
性别、年龄:男性35人,女性48人(包括宫巢、乳腺癌)。最高年龄1919年生(83岁),最低年龄1985年生(17岁),平均年龄54岁(以2002年计)。诊断确定依据:经一级教学医院者17人,二及区域医院者58人,三级地区医院者8人。
诊断确定后,经三级以内大医院、或自服药物无效而参与本试验者73人,直接参与者10人,共计83人。
经试验结果,显效26人、有效42人,合计有效者68人,占82%;无效者12人、不详者3人,合计无效者15人,占18%。各癌种别人数、效率如下表。
癌种别 | 人数 | 显效 | 有效 | 无效 | 不详 |
肺 | 17 | 3 | 11 | 2 | 1 |
淋巴 | 11 | 3 | 8 | 0 | 0 |
口腔、鼻咽、喉舌、甲状腺等 | 13 | 4 | 6 | 3 | 0 |
乳 | 11 | 6 | 3 | 1 | 1 |
宫巢附件 | 10 | 2 | 7 | 0 | 1 |
骨 | 5 | 2 | 0 | 3 | 0 |
膀胱、摄护腺 | 6 | 2 | 3 | 1 | 0 |
肠部 | 5 | 1 | 2 | 2 | 0 |
脑 | 2 | 1 | 1 | 0 | 0 |
血 | 1 | 0 | 1 | 0 | 0 |
肾 | 1 | 1 | 0 | 0 | 0 |
合计 | 83 | 26 | 42 | 12 | 3 |
比率 | 1 | 0.8192 | 0.1807 |
癌种转移统计
说明:
1、本统计的目的,是以实际癌患资料,剖析各种癌种,尤其是上、下部癌种转移的特性,以及放、化疗对此特性的影响;从而证明本案中类型机理的新创见,以填补治癌论据的不足。
2、标示在本案临床试验例的癌种别。是属于进行性的,而本统计是依据此83件资料,而寻用其原发性,以利于转移动态的追查。
3、上焦、是指横隔膜以上、包括颈、口腔、胸的上部,原发上焦癌者有51人;下焦、是指胰、肝、胃以下,包括肾、骨的下部,原发下焦癌者有32人。放、是指放射电疗;化、是指化学药物滴注疗法;该83例中、经放、化疗者3 1人,未经放、化疗者52人。
4、转下是指原发上焦的癌向下转移、或转移下焦;转上、是指癌的向上转移、或转移上焦;平转、是指原发上焦或下焦的癌,横向转移附近器官;不转、是指癌在原器官不动,或经割除、放、化疗的后,仍然再生、扩散于原器官。
统计图表:
上焦癌51人 | 转下 | 平转 | 不转 |
经放化疗21人 | 10人 | 5人 | 6人 |
未经放化疗30人 | 1人 | 5人 | 24人 |
计51人 | 11人 | 10人 | 30人 |
下焦癌32人 | 转下 | 平转 | 不转 |
经放化疗10人 | 5人 | 3人 | 2人 |
未经放化疗22人 | 6人 | 3人 | 13人 |
计32人 | 11人 | 6人 | 15人 |
1、上、下焦癌转下、转上的比较:
A、混合(不论是否经化、放疗)
上焦癌转下11/51=0.21,下转癌转上11/32=0.34
B、不经化、放疗
上焦癌转下1/30=0.033,下焦癌转上6/22=0.272
0.21<0.34,0.03<0.27
则上焦癌转下<下焦癌转上;在不经化、放疗的情况下,上焦癌转下是下焦癌转上的1/8。
2、上、下焦癌转移(包括平转)的比较:
A、混合(不论是否经化、放疗)
上焦癌转移11/51+10/51=21/51=0.412
下焦癌转移11/32+6/32=17/32=0.531
B、不经化、放疗
上焦癌转移1/30+5/30=6/30=0.200
下焦癌转移6/22+3/22=9/22=0.409
0.412<0.53,0.20<0.41
则上焦癌的转移,略少于下焦癌的转移;在不经化、放疗的情况下、上焦癌的转移是下焦癌转移的1/2。
3、化、放疗与不经化、放疗的转上、转下,以及转移的比较:
A、上焦转下与下焦转上;
上焦经化、放转下10/21=0.476
上焦不经化、放转下1/30=0.033
下焦经化、放转上5/10=0.5
下焦不经化、放转上6/22=0.272
B、上焦转移(含平转)与下焦转移;
上焦经化、放转移10/21+5/21=15/21=0.71
上焦不经化、放转移1/30+5/30=6/30=0.20
下焦经化、放转移5/10+3/10=8/10=0.80
下焦不经化、放转移6/22+3/22=9/22=0.409
上焦经化、放与否的比例
转下-0.476>0.033=14.5倍
转移-0.710>0.20=3.5倍
下焦经化、放与否的比例
转上-0.50>0.27=1.8倍
转移-0.80>0.41=1.9倍
结论:
1、由上1的统计可知,上焦癌转下的0.21<下焦癌转上的0.34;在不经化、放疗的情况下,上焦癌转下的0.03、只是下焦癌转上的1/8。
2、由上2的统计可知,上焦癌转移的0.412略少于下焦癌转移的0.53;在不经化、放疗的状况下,上焦癌的转移是下焦癌转移的1/2。
3、由上3的统计可知,经放、化疗的上焦癌转下,是不经化、放疗转下的14.5倍,转移是3.5倍,故上焦癌的化、放疗显然有催促转下、转移的敝端。经化、放疗的下焦癌,转上是不经化、放疗的1.8倍,转移是1.9倍,在下焦癌种具有转上本能的影响下,其严重性远低于上焦癌种。
4、综上所述,兹再重点归纳为A、上焦癌种向下转移的能度甚低,且低于本位的平转、上转。B、上焦癌的化、放疗甚不利于癌患,经化、放疗后、转移能度增加3.5倍,向下转移能度竟高达14.5倍。C、下焦癌种本就具有向上转移的高能度,在不经化、化疗的状况下,是上焦癌种向下转移的8倍;经化、放疗后;其转上、转移的能度影响略少。D、本统计资料因环境因素而略有不足,乃望较具规模的癌研机构,依此方式再行统计,必有更为确凿的发现。
临床试验标准例
在本发明书内,仅举出其中九个案例作简要说明,其余65案件及详细说明,如附件一所示。
(1)NO.1洪××小姐、肺癌、1985年生(17岁)、
2000年12月,经台南某二级大医院科学检验,发现右膝盖骨下骨癌,12月26日截切右下肢,并施予全程化疗治疗。
2001年8月,因咳嗽声紧促,呼吸障碍,经原院检验,发现癌细胞转移肺部,即行开刀,因见癌体机超大,难以手术,故再行缝合。
2001年9月14日参与本试验,至同年10月26日主症状明显改善,已不觉痛苦、4疗程后,主症状完全消失,后即断、续用药。2002年2月9日,右足骨癌切除处、肿热发炎,用本发明药物、略加他药,二疗程内痊愈。
(2)NO、9、詹××女士、肺癌、1942年生(60岁)
1995年乳腺癌切除;1998年11月转移右锁骨上淋巴癌,经彰化某二级宗教医院检验确定,并施与化疗、放疗。2000年4月转移左腋下,经原院切除,再予化疗。2001年1月再检,发现转移为肺癌。
2001年2月1日参与本试验;症候A、喘急,胸中压迫感,咳嗽则胸内疼痛。B、腹腰肿胀感,下腹按的痛。C、右手臂因化放疗过敏反应,而淋巴肿胀、象皮肿。D、足胫肿。
2001年3月23日,主症状或痊或明显改善,经原医院检验,癌肿粒不再发生,增大,情况稳定;至疗程结束,诸证状多痊,唯化、放疗后遗的右手臂象皮肿改善有限。
(3)NO.18,陈××女士,淋巴癌,1951年生(51岁)
先是1999年3月,经台南某二级专科医院宫颈癌检确,同月17日开刀切除宫巢、放射电疗28次,接续化疗5周,每周一次。病况未见改善,乃转以鸡尾酒疗法治疗无效。化疗后15天,足胫肿,右上肢腰骨持续剧痛;再转入高雄某二级大医院检验,证实已转移入淋巴、骨髓内,宣布右手已残废,并移入安宁病房,以麻醉剂止痛,作为最后安顿。
2000年8月10日,由亲属搀扶前来参兴本试验,主症状A、左琐骨上淋巴癌肿块约5CM,B、右上肢运动不能、残废,C、腰背持续疼痛,须服用麻醉剂止痛,D、宫巢切除处微痛,E、左足化、放疗遗肿胀。其它食量每顿约5匙,虚弱,行动艰难,大便闭结,小便量少。
2000年8月22日,腰背,右肩胛的疼痛,在半疗程内明显改善,不用麻醉剂,下腹舒坦,二便通畅。9月6日主症状再改善,无痛苦感受,左琐骨上淋巴癌肿块消退二分的一,右手已可活动。后因误食某直销的健康食品,而癌肿块再肿,右手臂又剧痛,用药至10月17日,项下癌块消,右手臂复元,腰背持续的疼痛完全消失。11月5日左琐骨上癌块仅存0.2CM,其余生活、起居一如健康人。至2002年6月不复发。
(4)No.23,郭××女士,淋巴癌,1946年生(56岁)
1999年10月,南部某一级教学医院诊断确定为膀胱癌,并施与开刀治疗;2000年5月追纵检查,发现转移直肠癌,开刀,因故不予切除,而施行化学滴注5次,不久,左琐骨上出现淋巴癌肿块,约3.5CM,确定转移为淋巴癌,并予插肾导尿管,背尿袋,原院束手。
2001年3月10日参与本试验,主症状A、左琐骨上淋巴癌肿块约3.5CM,B、下腹绞痛、腰臀酸痛不支。C、大便先急后重,排便困难。其它食欲不佳,虚弱、体力不支等。
2001年3月21日,B、C症状明显改善。3月28日A的淋巴癌肿块渐消,但腰臀酸痛又起。4月8日主症状再改善。5月9日服用直销健康食品(品物同前例),致淋巴癌再肿。5月16主副症状持续改善,并维持30天以上。
(5)NO.29,温××先生,口腔癌,1924年生(78岁)
宿有糖尿病,1998年12月16日经某二级大医院诊断为口腔癌,经原院药物治疗,以及服用多种药物,病况仍持续恶化。
1999年10月17日参与本试验;主症状A、口腔近咽处溃烂,左颊,齿龈间呈现癌肿粒,颔下腺肿硬,开启障碍。B、腹中痞胀。C、夜间咳嗽。其它疲劳倦怠,体力不支,行动艰难。
1999年10月31日溃烂病象改善,领下腺肿消,痞胀,嗽均减。11月17日主症状再改善,精神体力转佳;饭前血糖已正常(并未另加糖尿病药)。12月2日原有癌痛苦消失,已可帮忙养猪及其它工作。及至2000年4月原癌症状未再发生。
(6)NO.42,邱××女士,乳腺癌,1954年生(48岁)
先在南部某一级医院检验确定为乳腺癌,并在其医师私设诊所接受不详治疗,因病况不见改善,于2000年4月14日转于某二级军医院再确定,并接受内服药医疗,院方建议化疗未成。
2000年4月25日起,参与本试验;主症状A、右乳房内,外侧呈现肿硬癌块。乳头微有溃疡。其它习常便闭、肠鸣。
2000年5月9日第一疗程内,癌肿块已渐软化,因乐物通透关系,呈可接受的抽痛,5月24日癌肿块软化、缩小、抽痛微。6月9日乳癌肿块按摸的消退,乳头痊,结痂脱落。
(7)NO.54陈××女士,卵巢癌,1962年生(40岁)
受试者是试验单位他症旧患者;经高雄某二医院诊断确定是左卵巢癌后,即于1999年9月18日直接参与本试验。主症状A、下腹偶发胀痛。B、胃脘痞胀。C、阴部常有黄杂色分泌物。其它有习常便闭,小便频等症。
1999年9月18日开始接受本试验,因家庭变故关系,不能连续用药,至2000年5月3 1日,仅用药5疗程,主副症状基本上消失。并于2000年5月5日经原诊断医院细扫瞄,左卵巢瘤消退无纵迹,察其它部位亦无转移、扩散征象。2002年5月追纵查探,犹保持健康状态。
(8)NO.63,温××先生,骨癌,1952年生(45岁)
1996年12月,高雄某二级医院检验确定,多发性骨髓癌,谓已向上扩散三点,并发糖尿病;经射电疗15次完成,但病况却持续恶化。
1997年6月3日参与本试验;症状A、下肢腿肌腱消失,腿臀骨内疼痛不支,足胫肿胀,足痿,举步艰难。B、咳嗽、咽内多痰涎。C、腹中痞胀、不舒。其它,口渴,小便频短,色赤,偶便闭,食欲异常,不退反增。
1997年6月15日,用药一疗程内,已可步行,疼痛减至可忍受限度,足胫肿消,但腹部电疗处不舒服。7月11日,行动已正常,咳嗽减轻。8月3日经原医院检测,癌细胞已告稳定,AFP正常,糖尿AC200,8月15日,红、白血球接近正常。8月28日下肢腿上肌肉复生,糖尿已正常。10月9日原医院再行检测,癌细胞已被控制,无作怪能力,血球均正常。
(9)NO.68,黄××先生,膀胱癌,1954年生(46岁)
1999年12月,经高雄某二级大医院检验确定为大肠癌,12月18日切除,并置人工肛门。2000年3月追纵检查,发现转移膀胱,经手术切开、刮除,再予缝合,不久再检验发现癌细胞再生。
2000年6月22日参与本试验,主症状A、膀胱局部有刺痛感觉,小便频短。B、右下腹侧疼痛。其它有食欲不振,疲劳倦怠等副症状。7月4日主症状A消失,B、改善,但逢咳嗽则有抽搐痛。7月17日主症状A、B均消失。
经过600天后,于2002年3月20日因他疾来诊,探知所有大肠癌,膀胱癌在此期间内未再发生症状,且自2000年8月开始,即已正常生活、工作。
Claims (3)
1、一种治疗淋巴结关系型癌症的中药,其特征在于它是由下述重量配比的原料制成的:党参1.94%-3.94%、黄芪1.94%-3.94%、薏苡仁1.94%-3.94%、山佩兰1.94%-3.94%、橘皮1.94%-3.94%、爵床1.94%-3.94%、夏枯草1.94%-3.94%、凉粉草1.94%-3.94%、栀子1.94%-3.94%、连翘1.94%-3.94%、赤芍1.94%-3.94%、大黄1.94%-3.94%、虫1.94%-3.94%、白花蛇舌草1.94%-3.94%、扛板归1.94%-3.94%、山豆根1.94%-3.94%、木槿皮1.94%-3.94%、天南星1.94%-3.94%、半边莲1.94%-3.94%、白蔹1.94%-3.94%、漏芦1.94%-3.94%、石苇1.94%-3.94%、乳香1.94%-3.94%、没药1.94%-3.94%、蚤休1.94%-3.94%、败酱1.94%-3.94%、白芷1.94%-3.94%、射干1.94%-3.94%、蒲公英1.94%-3.94%、螺厣草1.94%-3.94%、皂荚1.94%-3.94%、独活1.94%-3.94%、麻黄1.94%-3.94%、升麻1.94%-3.94%。
2、如权利要求1所述的治疗淋巴结关系型癌症的中药,其特征在于上述各原料重量配比为均等。
3、如权利要求1所述的治疗淋巴结关系型癌症的中药,其特征在于是利用茯苓作为赋形剂。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031229891A CN1187081C (zh) | 2003-04-23 | 2003-04-23 | 一种治疗淋巴结关系型癌症的中药 |
US10/457,457 US7005146B2 (en) | 2003-04-23 | 2003-06-10 | Complex prescription of chinese medicine for the treatment of extensive cancer |
TW93101904A TWI260226B (en) | 2003-04-23 | 2004-01-28 | Complex prescription of Chinese medicine for the treatment of extensive cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031229891A CN1187081C (zh) | 2003-04-23 | 2003-04-23 | 一种治疗淋巴结关系型癌症的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1449812A CN1449812A (zh) | 2003-10-22 |
CN1187081C true CN1187081C (zh) | 2005-02-02 |
Family
ID=28684419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031229891A Expired - Fee Related CN1187081C (zh) | 2003-04-23 | 2003-04-23 | 一种治疗淋巴结关系型癌症的中药 |
Country Status (2)
Country | Link |
---|---|
US (1) | US7005146B2 (zh) |
CN (1) | CN1187081C (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007012335A1 (fr) * | 2005-07-26 | 2007-02-01 | Djamila Souiki | Traitement de tout types de cancer, kystes, fibromes, des infections, inflammations, anxiete, migraines, desequilibre hormonal, ulcere, asthme, maladie de crohne, eczema, psoriasis, rhumatisme, acne. |
PL2341918T3 (pl) * | 2008-09-25 | 2018-08-31 | Lifebiotic Medical Research Ltd | Preparaty roślinne |
WO2011011214A1 (en) * | 2009-07-21 | 2011-01-27 | Pinecrest International Corp Limited | A pharmaceutical composition for the treatment of open wounds |
US9520772B2 (en) | 2010-11-09 | 2016-12-13 | Tdk-Lambda Corporation | Multi-level voltage regulator system |
US8934267B2 (en) | 2010-11-09 | 2015-01-13 | Tdk-Lambda Corporation | Loosely regulated feedback control for high efficiency isolated DC-DC converters |
KR101814760B1 (ko) | 2011-02-11 | 2018-01-03 | 주식회사 케미메디 | 패장근 추출물을 유효성분으로 함유하는 뇌암의 예방 및 치료용 약학적 조성물 |
CN102716245B (zh) * | 2011-03-31 | 2014-05-28 | 丽珠医药集团股份有限公司 | 中药组合物在制备抗71型肠道病毒的药物中的用途 |
US8858953B2 (en) | 2011-05-09 | 2014-10-14 | Yu-Hwa Peter Sheng | Herbal composition for treating cancer |
EP2570035B1 (de) * | 2011-09-15 | 2014-06-18 | Symrise AG | Verwendung von Neoflavonoiden zur Geschmacksmodifizierung |
EP2570036B1 (de) * | 2011-09-15 | 2014-06-18 | Symrise AG | Verwendung bestimmter Neoflavonoide zur Verstärkung und/oder Erzeugung eines süßen sensorischen Eindruckes |
WO2014069695A1 (ko) * | 2012-10-31 | 2014-05-08 | 주식회사 한국전통의학연구소 | 유향 추출물을 포함하는 췌장암 치료용 조성물 및 건강 기능성 식품 |
WO2014092682A1 (en) * | 2012-12-11 | 2014-06-19 | Avon Products, Inc. | Serissa japonica extracts and methods of use |
CN106138344A (zh) * | 2015-02-17 | 2016-11-23 | 钟森 | 青皮的新用途 |
WO2019060759A1 (en) | 2017-09-21 | 2019-03-28 | Dana-Farber Cancer Institute, Inc. | ISOLATION, PRESERVATION, COMPOSITIONS AND USES OF PLANT EXTRACTS JUSTICIA |
CN110484653B (zh) * | 2019-09-27 | 2023-05-19 | 广东省科学院南繁种业研究所 | Ssr分子标记引物、仙草品种的鉴定方法及试剂盒 |
-
2003
- 2003-04-23 CN CNB031229891A patent/CN1187081C/zh not_active Expired - Fee Related
- 2003-06-10 US US10/457,457 patent/US7005146B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20040219226A1 (en) | 2004-11-04 |
CN1449812A (zh) | 2003-10-22 |
US7005146B2 (en) | 2006-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1187081C (zh) | 一种治疗淋巴结关系型癌症的中药 | |
CN104187172B (zh) | 用于治疗乌龟肠胃炎病的功能性饲料及其制备方法 | |
CN103719494B (zh) | 一种牛蒡子通便润肠保健茶及其制备方法 | |
CN102784363A (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN104305205B (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
CN103933509B (zh) | 用于治疗淡水鱼水霉病的药物及其制备方法 | |
CN103536826B (zh) | 一种治疗阴道炎的中药组合物及其制备方法 | |
CN102886014B (zh) | 一种清血消炎的抗肿瘤药物 | |
CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN104605372A (zh) | 一种基于恶性肿瘤放疗患者的营养药膳及制备方法 | |
CN104189413A (zh) | 用于治疗乌龟肠胃炎病的药物组合物及其制备方法 | |
CN114748603A (zh) | 一种防治新冠病毒肺炎变异或复阳的药食同源组合物和应用 | |
CN104784508B (zh) | 用于提高恶性肿瘤患者免疫功能的中药制剂的制备方法 | |
CN105617268A (zh) | 一种治疗鳞屑角化型脚气的药物 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
CN104784509B (zh) | 用于提高恶性肿瘤患者免疫功能的中药制剂 | |
CN109432355A (zh) | 一种抗肝癌的中药组合物及其制备方法 | |
TWI260226B (en) | Complex prescription of Chinese medicine for the treatment of extensive cancer | |
CN103028028B (zh) | 一种治疗原发性肝癌的中药 | |
CN101279040B (zh) | 中药活性防癌疫苗及其制备方法 | |
CN106110204A (zh) | 一种提高免疫力的蒲公英口服液及其制备方法 | |
CN105727036A (zh) | 一种用于防治鸡马立克氏病的中药组合物及其制备方法 | |
CN100350953C (zh) | 一种治疗病毒感染性高热病的药物组合物及其制备方法 | |
CN104800519A (zh) | 一种治疗冲任失调型乳腺增生的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050202 Termination date: 20120423 |